var title_f15_46_16096="Three point cast molding";
var content_f15_46_16096=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52462&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three-point cast molding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Interosseous mold technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16096=[""].join("\n");
var outline_f15_46_16096=null;
var title_f15_46_16097="Flucloxacillin: International drug information";
var content_f15_46_16097=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flucloxacillin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Flix (JP);",
"     </li>",
"     <li>",
"      Flupen (IT);",
"     </li>",
"     <li>",
"      Staphycid (LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Flucloxacillin Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible infections due to gram-positive organisms, including Beta-lactamase-producing Staphylococci",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Take at least 30 minutes before food:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;2 years: 62.5 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-10 years: 125 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 250-500 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Adults: 250 mg every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Adults: 250 mg-2 g every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Injection, powder for reconstitution: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, oral: 125 mg/5 mL (100 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10385 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16097=[""].join("\n");
var outline_f15_46_16097=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303752\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978871\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978873\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978876\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978872\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821183\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978875\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10385|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16098="Osteoarthritis symptoms and diagnosis";
var content_f15_46_16098=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/46/16098/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16098/contributors\" id=\"au6719\">",
"       Kenneth C Kalunian, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/46/16098/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16098/contributors\" id=\"se247\">",
"       Peter Tugwell, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?15/46/16098/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16098/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?15/46/16098?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OSTEOARTHRITIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Osteoarthritis (OA) is a common type of arthritis in which there is a gradual loss of cartilage from the joints (",
"     <a class=\"graphic graphic_figure graphicRef73149 \" href=\"UTD.htm?28/20/28993\">",
"      figure 1",
"     </a>",
"     ). Common osteoarthritis symptoms include pain, stiffness, some loss of joint motion, and changes in the shape of affected joints. Although OA can affect almost any joint, it most often affects the hands, knees, hips, and spine.",
"    </p>",
"    <p>",
"     Osteoarthritis is a chronic condition that gradually worsens over time; however, there are several measures that may slow its progression and control symptoms. The diagnosis of OA is the first step in ensuring the appropriate treatment of osteoarthritis.",
"    </p>",
"    <p>",
"     This article reviews the symptoms and diagnostic tests that may be used for people with osteoarthritis. Treatment of OA is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"      \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF OSTEOARTHRITIS",
"     </span>",
"    </p>",
"    <p>",
"     There are two main types of osteoarthritis, which have differing causes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Idiopathic osteoarthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Idiopathic OA has no identifiable cause. It may be localized (confined to one or two joints) or generalized (present in three or more joints).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Secondary osteoarthritis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Secondary OA is caused by an underlying condition, such as a joint injury, accumulation of calcium inside the joint, other bone and joint conditions (eg, rheumatoid arthritis), or a medical condition, such as diabetes.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      OSTEOARTHRITIS RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     A number of factors can increase the risk of developing osteoarthritis; most people with OA have one or more of these factors (",
"     <a class=\"graphic graphic_table graphicRef77930 \" href=\"UTD.htm?34/63/35835\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Age",
"     </span>",
"     &nbsp;&mdash;&nbsp;Advancing age is one of the strongest risk factors for OA. The condition rarely occurs in people younger than age 40, but at least 80 percent of people over age 55 have some x-ray evidence of the disorder. However, not all people with arthritis on an x-ray have joint pain or other joint problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Gender",
"     </span>",
"     &nbsp;&mdash;&nbsp;For unknown reasons, women are between two and three times more likely than men to develop OA.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Obesity",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are obese are at high risk of developing OA. Weight loss may reduce this risk.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Occupation",
"     </span>",
"     &nbsp;&mdash;&nbsp;OA of the knee has been linked to certain occupations that require frequent squatting and kneeling, including cotton processing, dock work, shipyard work, and carpentry.",
"    </p>",
"    <p>",
"     OA of the hip has been linked to farm work, construction work, and other activities that require heavy lifting, prolonged standing, or walking several miles each day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Sports",
"     </span>",
"     &nbsp;&mdash;&nbsp;The risk of OA is increased in those who participate in certain sports, including wrestling, boxing, pitching in baseball, cycling, parachuting, cricket, gymnastics, ballet dancing, soccer, and football; in contrast, running does not appear to increase the risk of OA.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      OSTEOARTHRITIS SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The symptoms of OA usually begin after age 40 and can vary considerably from one person to another (",
"     <a class=\"graphic graphic_table graphicRef77930 \" href=\"UTD.htm?34/63/35835\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;The main symptom of OA is joint pain that is worse with activity and is relieved by rest. In severe cases, the pain may also occur at rest or at night. The pain usually occurs near the affected joint; however, in some cases, the pain may be referred to other areas. For example, the pain of OA of the hip may actually be felt in the knee.",
"    </p>",
"    <p>",
"     Joints affected by OA may be tender to the touch. The level of pain is typically constant over time. Any sudden increases in the level of pain may indicate recent injury or an underlying condition such as gout. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"      \"Patient information: Gout (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Stiffness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Morning stiffness is a common symptom of osteoarthritis. This stiffness usually resolves within 30 minutes of rising, but it may recur throughout the day during periods of inactivity. Some people note a change in symptoms related to the weather.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Swelling (effusion)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Osteoarthritis may cause a type of joint swelling called an effusion, which results from the accumulation of excess fluid in the joint.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Crackling or grating sensation (crepitus)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Movement of a joint affected by osteoarthritis may cause a crackling or grating sensation called crepitus. This sensation likely occurs because of roughening of the normally smooth surfaces inside the joint.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Bony outgrowths (osteophytes)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Osteoarthritis often causes outgrowths of bone called osteophytes or bone spurs. These bony protuberances can be felt under the skin near joints and typically enlarge over time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Symptoms in specific joints",
"     </span>",
"     &nbsp;&mdash;&nbsp;Osteoarthritis does not affect all joints equally. The condition most commonly affects the fingers, knees, hips, and spine; it rarely affects the elbow, wrist, and ankle. Furthermore, it often affects joints on one side of the body differently than on the other side.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      OSTEOARTHRITIS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     There is no single sign, symptom, or test that can diagnose OA. Instead, the diagnosis is based on a consideration of several factors, including the characteristic symptoms of osteoarthritis and the results of laboratory tests and x-rays.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Diagnostic criteria",
"     </span>",
"     &nbsp;&mdash;&nbsp;Formal criteria are often used to diagnose osteoarthritis in specific joints.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoarthritis of the knee &mdash; The criteria for OA of the knee include the presence of knee pain plus at least three of the following characteristics:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Age greater than 50 years",
"      </li>",
"      <li>",
"       Morning stiffness lasting less than 30 minutes",
"      </li>",
"      <li>",
"       Crackling or grating sensation (crepitus)",
"      </li>",
"      <li>",
"       Bony tenderness of the knee",
"      </li>",
"      <li>",
"       Bony enlargement of the knee",
"      </li>",
"      <li>",
"       No detectable warmth of the joint to the touch",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Laboratory tests and x-rays are often used in addition to these criteria.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoarthritis of the hand &mdash; The criteria for OA of the hand include the presence of hand pain plus at least three of the following characteristics:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Bony enlargement of at least 2 or more of 10 selected joints",
"      </li>",
"      <li>",
"       Bony enlargements of two or more distal interphalangeal (DIP) joints",
"      </li>",
"      <li>",
"       Fewer than three swollen metacarpophalangeal (MCP) joints",
"      </li>",
"      <li>",
"       Deformity of at least 1 of the 10 selected joints",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Osteoarthritis of the hand can often be diagnosed on the basis of these criteria alone, and laboratory tests and x-rays may be unnecessary.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoarthritis of the hip &mdash; The diagnosis of OA of the hip is relies on the results of laboratory tests and x-rays. The criteria include the presence of hip pain plus at least two of the following characteristics:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       A normal erythrocyte sedimentation rate (ESR)",
"      </li>",
"      <li>",
"       The presence of bony outgrowths (osteophytes) on x-rays",
"      </li>",
"      <li>",
"       The presence of joint space narrowing on x-rays, indicating a loss of cartilage",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Laboratory tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laboratory tests may be recommended to help diagnose osteoarthritis by ruling out conditions with similar symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;X-rays are often helpful for tracking the status of osteoarthritis over time, but x-rays may appear normal during the early stages.",
"    </p>",
"    <p>",
"     Other types of imaging tests, such as ultrasound and magnetic resonance imaging (MRI), may be used to detect damage to cartilage, ligaments, and tendons, which cannot be seen on x-ray.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      COURSE OF OSTEOARTHRITIS",
"     </span>",
"    </p>",
"    <p>",
"     Osteoarthritis generally worsens slowly over time, although it stabilizes in some people. In those whose pain and joint stiffness worsens over time, there is usually intermittent worsening (worsening, then stabilization for a period).",
"    </p>",
"    <p>",
"     Some people with osteoarthritis are able to function normally despite pain while others may have difficulty with even simple tasks as a result of pain. Exercise may help to prevent loss of strength and may decrease the chances of becoming disabled.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H23\">",
"     <span class=\"h1\">",
"      OSTEOARTHRITIS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of osteoarthritis is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"      \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H24\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H241\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11167559\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/34/23075?source=see_link\">",
"      Patient information: Hip replacement (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/22/9571?source=see_link\">",
"      Patient information: Arthritis and exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=see_link\">",
"      Patient information: Meniscal tear (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/59/12211?source=see_link\">",
"      Patient information: Paget disease of bone (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11167574\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/57/24467?source=see_link\">",
"      Patient information: Gout (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2538?source=see_link\">",
"      Nonpharmacologic therapy of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/40994?source=see_link\">",
"      Patient guidelines for weight-resistance training in osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/23/14714?source=see_link\">",
"      Pharmacologic therapy of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"      Weight-resistance training in patients with osteoarthritis",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/arthritis.html\">",
"        www.nlm.nih.gov/medlineplus/arthritis.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/Health_Info/Arthritis/default.asp\">",
"        www.niams.nih.gov/Health_Info/Arthritis/default.asp",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute on Aging",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nia.nih.gov/health/publication/arthritis-advice\">",
"        www.nia.nih.gov/health/publication/arthritis-advice",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"        www.rheumatology.org/practice/clinical/patients/index.asp",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Arthritis Forum",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://arthritis.about.com/forum\">",
"        file://arthritis.about.com/forum",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?15/46/16098/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?15/46/16098?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16098/abstract/1\">",
"      Hochberg MC. Prognosis of osteoarthritis. Ann Rheum Dis 1996; 55:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16098/abstract/2\">",
"      Guidelines for the initial evaluation of the adult patient with acute musculoskeletal symptoms. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16098/abstract/3\">",
"      Wu CW, Morrell MR, Heinze E, et al. Validation of American College of Rheumatology classification criteria for knee osteoarthritis using arthroscopically defined cartilage damage scores. Semin Arthritis Rheum 2005; 35:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16098/abstract/4\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990; 33:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16098/abstract/5\">",
"      Altman R, Alarc&oacute;n G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f15_46_16098=[""].join("\n");
var outline_f15_46_16098=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OSTEOARTHRITIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF OSTEOARTHRITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           OSTEOARTHRITIS RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           OSTEOARTHRITIS SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           OSTEOARTHRITIS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           COURSE OF OSTEOARTHRITIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H23\">",
"           OSTEOARTHRITIS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H24\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/20/28993\" title=\"figure 1\">",
"           Osteoarthritis PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?34/63/35835\" title=\"table 1\">",
"           Effects of OA PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16099="Paromomycin: Drug information";
var content_f15_46_16099=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Paromomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7956?source=see_link\">",
"    see \"Paromomycin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/55/9075?source=see_link\">",
"    see \"Paromomycin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humatin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Amebicide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intestinal amebiasis:",
"     </b>",
"     Oral: 25-35 mg/kg/day in 3 divided doses for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infection by",
"     </b>",
"     <b>",
"      <i>",
"       Dientamoeba fragilis",
"      </i>",
"     </b>",
"     : Oral: 25-30 mg/kg/day in 3 divided doses for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infection by",
"     </b>",
"     <b>",
"      <i>",
"       Cryptosporidium",
"      </i>",
"     </b>",
"     <b>",
"      (unlabeled use):",
"     </b>",
"     Oral: Adults with AIDS: 1.5-2.25 g/day in 3-6 divided doses for 10-14 days (occasionally courses of up to 4-8 weeks may be needed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tapeworm (fish, dog, bovine, porcine):",
"     </b>",
"     Oral: 1 g every 15 minutes for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hepatic coma:",
"     </b>",
"     Oral: 4 g/day in 2-4 divided doses for 5-6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dwarf tapeworm:",
"     </b>",
"     Oral: 45 mg/kg/dose every day for 5-7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F206531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/55/9075?source=see_link\">",
"      see \"Paromomycin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intestinal amebiasis:",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infection by",
"     </b>",
"     <i>",
"      Dientamoeba fragilis",
"     </i>",
"     : Children: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tapeworm (fish, dog, bovine, porcine):",
"     </b>",
"     Oral: Children: 11 mg/kg every 15 minutes for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dwarf tapeworm:",
"     </b>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute and chronic intestinal amebiasis; hepatic coma",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F206536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cryptosporidiosis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F206538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Diarrhea, abdominal cramps, nausea, vomiting, heartburn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Eosinophilia, exanthema, headache, ototoxicity, pruritus, rash, secondary enterocolitis, steatorrhea, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to paromomycin or any component of the formulation; intestinal obstruction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative bowel lesions: Use with caution in patients with possible or proven ulcerative bowel lesions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Paromomycin may cause malabsorption of xylose, sucrose, and fats.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10236736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paromomycin is poorly absorbed when given orally. Because it does not reach the maternal serum, it would not be expected to adversely affect the fetus. No adverse effects were observed in two infants whose mothers took paromomycin during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F206512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Paromomycin is poorly absorbed when given orally.  Because it does not reach the maternal serum, it would not be expected to distribute into human milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Paromomycin Sulfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (100): $567.00",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aminosidine (JP);",
"     </li>",
"     <li>",
"      Gabbroral (BE, IT, LU);",
"     </li>",
"     <li>",
"      Gabbryl (ID);",
"     </li>",
"     <li>",
"      Gabrosidina (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Humagel (FR);",
"     </li>",
"     <li>",
"      Humatin (AT, CH, DE, ES, IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on ameba; has antibacterial activity against normal and pathogenic organisms in the GI tract; interferes with bacterial protein synthesis by binding to 30S ribosomal subunits",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor oral absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (100% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Danziger LH, Kanyok TP, and Novak RM, &ldquo;Treatment of Cryptosporidial Diarrhea in an AIDS Patient With Paromomycin,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1993, 27(12):1460-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16099/abstract-text/8305777/pubmed\" id=\"8305777\" target=\"_blank\">",
"        8305777",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Parasitic Infections,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1017):1-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16099/abstract-text/9442765/pubmed\" id=\"9442765\" target=\"_blank\">",
"        9442765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu LX and Weller PF, &ldquo;Antiparasitic Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(18):1178-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16099/abstract-text/8602186/pubmed\" id=\"8602186\" target=\"_blank\">",
"        8602186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9742 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16099=[""].join("\n");
var outline_f15_46_16099=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206519\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206540\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206520\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206531\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206521\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206506\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206493\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206507\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206536\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206538\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206497\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299825\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206502\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206516\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10236736\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206512\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323618\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038719\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206496\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206509\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9742\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9742|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/49/7956?source=related_link\">",
"      Paromomycin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/55/9075?source=related_link\">",
"      Paromomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16100="Bronchiectasis Lateral";
var content_f15_46_16100=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63795&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral chest radiograph demonstrating ring shadows of cystic bronchiectasis (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal lateral chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16100=[""].join("\n");
var outline_f15_46_16100=null;
var title_f15_46_16101="Guaifenesin: Drug information";
var content_f15_46_16101=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/55/26484?source=see_link\">",
"    see \"Guaifenesin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=see_link\">",
"    see \"Guaifenesin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allfen [OTC] [DSC];",
"     </li>",
"     <li>",
"      Bidex&reg;-400 [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; EX [OTC];",
"     </li>",
"     <li>",
"      Fenesin IR [OTC];",
"     </li>",
"     <li>",
"      Geri-Tussin [OTC];",
"     </li>",
"     <li>",
"      Humibid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Iophen NR [OTC];",
"     </li>",
"     <li>",
"      Liquituss GG [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; [OTC];",
"     </li>",
"     <li>",
"      Mucus Relief [OTC];",
"     </li>",
"     <li>",
"      Organ-I NR [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; 400 [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; [OTC];",
"     </li>",
"     <li>",
"      Robafen [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Expectorant [OTC];",
"     </li>",
"     <li>",
"      Siltussin SA [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Casero&trade; Chest Congestion Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control [OTC];",
"     </li>",
"     <li>",
"      Xpect&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Expectorant;",
"     </li>",
"     <li>",
"      Benylin&reg; E Extra Strength;",
"     </li>",
"     <li>",
"      Koffex Expectorant;",
"     </li>",
"     <li>",
"      Robitussin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Expectorant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cough (expectorant):",
"     </b>",
"     Oral: 200-400 mg every 4 hours to a maximum of 2.4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release tablet:",
"     </i>",
"     600-1200 mg every 12 hours, not to exceed 2.4 g/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F177618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=see_link\">",
"      see \"Guaifenesin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cough (expectorant):",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 months to 2 years: 25-50 mg every 4 hours, not to exceed 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-5 years: 50-100 mg every 4 hours, not to exceed 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-11 years: 100-200 mg every 4 hours, not to exceed 1.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenesin IR: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade; 400: 400 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's Mini-Melts&trade;: 50 mg/packet (12s) [contains magnesium 6 mg/packet, phenylalanine 0.6 mg/packet, sodium 2 mg/packet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's Mini-Melts&trade;: 100 mg/packet (12s) [contains magnesium 6 mg/packet, phenylalanine 1 mg/packet, sodium 3 mg/packet; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; EX: 100 mg/5 mL (118 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iophen NR: 100 mg/5 mL (480 mL) [contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquituss GG: 200 mg/5 mL (118 mL, 473 mL) [ethanol free, sugar free; contains potassium 30 mg/5 mL, propylene glycol, sodium 2 mg/5 mL; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's: 100 mg/5 mL (118 mL) [contains propylene glycol, sodium 3 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Tussin: 100 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Expectorant: 100 mg/5 mL (120 mL) [dye free, ethanol free, sugar free; contains benzoic acid; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Casero&trade; Chest Congestion Relief: 100 mg/6.25 mL (120 mL, 240 mL) [contains phenylalanine 5.5 mg/12.5 mL, sodium 32 mg/12.5 mL, sodium benzoate; honey-menthol flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Mucus Control: 200 mg/15 mL (295 mL) [contains propylene glycol, sodium 25 mg/15 mL, sodium benzoate; citrus blend flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 100 mg/5 mL (5 mL, 10 mL, 15 mL, 118 mL, 240 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin DAS-Na: 100 mg/5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Tussin: 100 mg/5 mL (480 mL) [ethanol free, sugar free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen: 100 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin SA: 100 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free, sugar free; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allfen: 400 mg [DSC] [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bidex&reg;-400: 400 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucus Relief: 400 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucus Relief: 400 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Organ-I NR: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xpect&trade;: 400 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humibid&reg; Maximum Strength: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg;: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Maximum Strength: 1200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet and granules",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush, chew, or break extended release tablets. Administer with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Help loosen phlegm and thin bronchial secretions to make coughs more productive",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GuaiFENesin may be confused with guanFACINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mucinex&reg; may be confused with Mucomyst&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Frequency not defined:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Uric acid levels decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Kidney stone formation (with consumption of large quantities)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC) notify healthcare provider if symptoms do not improve within 7 days, or are accompanied by fever, rash, or persistent headache. Do not use for persistent or chronic cough (as with smoking, asthma, chronic bronchitis, emphysema) or if cough is accompanied by excessive phlegm unless directed to do so by healthcare provider. Not for OTC use in children &lt;2 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on the limited available data, an increased risk of adverse birth outcomes has not been observed following maternal use of guaifenesin in pregnancy. Alcohol may be present in some liquid formulations of guaifenesin. If consumed in sufficient quantities during pregnancy, fetal alcohol syndrome may result. Guaifenesin has been investigated as an agent to improve cervical mucus and improve fertility.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16265849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if guaifensin is excreted in breast milk. The manufacturer recommends that caution be exercised when administering guaifensin to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F177591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Diabetic Tussin Mucus Relief Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (118 mL): $4.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Diabetic Tussin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (118 mL): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Mucinex Chest Congestion Child Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (118 mL): $7.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Mucus+Chest Congest Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Mucinex For Kids Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (12): $7.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (12): $7.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Diabetic Tussin EX Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (118 mL): $6.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (GuaiFENesin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (480 mL): $15.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin Chest Congestion Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (St Joseph Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/5 mL (60 mL): $2.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (GuaiFENesin ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (40): $17.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucinex Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200 mg (14): $11.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucinex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (40): $19.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Mucus-ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (20): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bidex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $36.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fenesin IR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $10.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (GuaiFENesin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $23.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Xpect Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $14.99",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Chamberlain`s Cough Remedy (ZA);",
"     </li>",
"     <li>",
"      Codimal (PH);",
"     </li>",
"     <li>",
"      Cofen (SG);",
"     </li>",
"     <li>",
"      Coldrex Broncho (PL);",
"     </li>",
"     <li>",
"      Deflenol (MX);",
"     </li>",
"     <li>",
"      Desbly (FR);",
"     </li>",
"     <li>",
"      Dextricyl (PH);",
"     </li>",
"     <li>",
"      Excaugh (HK);",
"     </li>",
"     <li>",
"      Fagusan N Losung (DE);",
"     </li>",
"     <li>",
"      Fenatussin (KP);",
"     </li>",
"     <li>",
"      Flemonex (PH);",
"     </li>",
"     <li>",
"      Fluidin (ES);",
"     </li>",
"     <li>",
"      Formulaexpec (ES);",
"     </li>",
"     <li>",
"      Guaiatussin (PL);",
"     </li>",
"     <li>",
"      Guajacuran (CZ);",
"     </li>",
"     <li>",
"      Guajazyl (PL);",
"     </li>",
"     <li>",
"      Gwajafen (PL);",
"     </li>",
"     <li>",
"      Lactocol (ES);",
"     </li>",
"     <li>",
"      Mucinex (MY);",
"     </li>",
"     <li>",
"      Pharmachem (PH);",
"     </li>",
"     <li>",
"      Probat (ID);",
"     </li>",
"     <li>",
"      Relaxil-G (HU);",
"     </li>",
"     <li>",
"      Resyl (AT, BG, CH, SE);",
"     </li>",
"     <li>",
"      Robitessin (VE);",
"     </li>",
"     <li>",
"      Robitussin (AE, AR, BH, CO, CR, CY, DO, EG, ES, GB, GT, HN, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MX, MY, NI, OM, PA, PH, PL, QA, SA, SV, SY, TH, TW, YE);",
"     </li>",
"     <li>",
"      Robitussin Chesty Cough (AU, NZ);",
"     </li>",
"     <li>",
"      Robitussin EX (HK);",
"     </li>",
"     <li>",
"      Sipla (ID);",
"     </li>",
"     <li>",
"      Suprekof (PH);",
"     </li>",
"     <li>",
"      Tintus (FI);",
"     </li>",
"     <li>",
"      Transpulmin G (PH);",
"     </li>",
"     <li>",
"      Vicks expectorant adulte (FR);",
"     </li>",
"     <li>",
"      Vicks Vaposyrup (BE);",
"     </li>",
"     <li>",
"      Wick Formula 44 Plus L (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing mucous viscosity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kuhn JJ, Hendley JO, Adams DF, et al, &ldquo;Antitussive Effect of Guaifenesin in Young Adults With Natural Colds,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1982, 6:713-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16101/abstract-text/ 6754274/pubmed\" id=\" 6754274\" target=\"_blank\">",
"        6754274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8503 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-218.189.88.190-50AA3700D9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16101=[""].join("\n");
var outline_f15_46_16101=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177632\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177602\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177618\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177603\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177570\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177585\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177584\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177639\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177630\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177588\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177574\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299423\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220718\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630929\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177606\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16265849\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177591\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177590\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177592\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177573\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177587\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8503\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8503|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/55/26484?source=related_link\">",
"      Guaifenesin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/5/5204?source=related_link\">",
"      Guaifenesin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16102="Bacterial adherence and other virulence factors for urinary tract infection";
var content_f15_46_16102=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial adherence and other virulence factors for urinary tract infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Alain Meyrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16102/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/46/16102/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial adhesion onto mucosal or urothelial cells is an important phenomenon determining bacterial virulence. Infection in the urinary tract is related in part to the ability of bacteria to adhere and colonize the gut, perineum, urethra, bladder, renal pelvicalyceal system, and renal interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Adhesion is particularly important when infection occurs in an anatomically normal urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ], but it is also important in recurrent cystitis and infection complicating indwelling bladder catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of bacterial adhesion in the urinary tract is complex. Uropathogenic Enterobacteriaceae are electronegative and too small to overcome repulsion by the net negative charge of epithelial cells. As a result, bacterial adhesion cannot occur in the absence of fimbriae or other (nonfimbrial) surface adhesion systems. These systems have favorable electrical charge and also promote adhesion via hydrophobicity. Fimbriae allow irreversible attachment to the uroepithelial cell membrane via adhesins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will primarily consider the role of bacterial adhesion as a virulence determinant of Escherichia coli and Proteus mirabilis, the two most common strains responsible for urinary tract infection (UTI). Virulence factors of E. coli are mainly responsible for promoting progression of the organism from the fecal reservoir into the bladder and occasionally the kidney. In comparison, virulence factors of P. mirabilis can induce UTI but are particularly important for the formation of infectious struvite stones.",
"   </p>",
"   <p>",
"    Bacterial virulence is not related to resistance to antimicrobial drugs. As an example, the most adherent strain of E. coli in the patient's intestinal flora is usually sensitive to most antibiotics.",
"   </p>",
"   <p>",
"    Multiple host-pathogen interactions are at work in urinary tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ESCHERICHIA COLI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virulence factors of uropathogenic E. coli include several properties pertaining to a small group of O-serotypes, including O1, O2, O4, O6, O7, O16, O18, and O75 (",
"    <a class=\"graphic graphic_figure graphicRef87632 \" href=\"UTD.htm?26/18/26920\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/10\">",
"     10",
"    </a>",
"    ]. The uropathogenicity of these serotypes can be illustrated by their prevalence in different populations. They are present in approximately 28 percent of isolates from the normal fecal flora; in comparison, they are responsible for roughly 80 percent of cases of pyelonephritis, 60 percent of cystitis, and 30 percent of asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study typing E. coli strains in women and their sexual partners showed that E. coli strains that had caused urinary tract infection were nine times more likely to have been passed between sexual partners than strains from women without infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/12\">",
"     12",
"    </a>",
"    ]. Strains with P. pili were also more likely to have been shared between partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adhesins",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several other factors that affect the uropathogenicity of E. coli. Of greatest importance is the presence of adhesins on the tip of bacterial fimbriae (also called pili) and on the bacterial surface itself (nonfimbrial adhesins) (",
"    <a class=\"graphic graphic_table graphicRef55155 \" href=\"UTD.htm?36/19/37179\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Most adhesins are lectins that recognize binding site conformations provided by oligosaccharide sequences present on the epithelial cell surface.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fimbrial adhesins",
"      </strong>",
"      &ndash; Two major fimbrial adherence systems have been identified in E. coli strains associated with UTI: pap and sfa (",
"      <a class=\"graphic graphic_table graphicRef55155 \" href=\"UTD.htm?36/19/37179\">",
"       table 1",
"      </a>",
"      ). The PAP adhesin, for example, is present on the tip of P fimbriae [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/13-17\">",
"       13-17",
"      </a>",
"      ]. The term P fimbriae stems from the fact that the PAP adhesin recognizes the human digalactoside P blood group determinants on human erythrocytes and urothelial cells, leading to increased adhesion (",
"      <a class=\"graphic graphic_picture graphicRef70223 \" href=\"UTD.htm?28/32/29184\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The binding of P fimbriae to blood group determinants has important implications for host susceptibility to infection. Women who are nonsecretors of histo-blood group antigens show increasing in vitro binding of E. coli to urothelial cells and are more likely to have recurrent urinary tract infections [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/18\">",
"       18",
"      </a>",
"      ]. Nonsecretors may have abnormal processing of gal-globoside glycolipid receptors resulting in the production of proteins that bind with more avidity to E. coli [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Nonfimbrial adhesins",
"      </strong>",
"      &ndash; Nonfimbrial adhesins encompass a diverse range of proteins, including AFA (",
"      <a class=\"graphic graphic_table graphicRef55155 \" href=\"UTD.htm?36/19/37179\">",
"       table 1",
"      </a>",
"      ). Other important adhesins include the AT (autotransporter) family of trimeric proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/20\">",
"       20",
"      </a>",
"      ]. Two of these proteins are highly homologous to the E. coli K-12 antigen 43 (Ag43a). This antigen promotes strong biofilm growth and its expression is associated with long-term E. coli persistence in the bladder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of adhesins in a given E. coli strain can be detected by phenotypic methods such as hemagglutination of agglutination of latex beads. However, phenotypic expression of uropathogenicity can be lost in cultured bacteria. As a result, genetic and molecular methods have been devised to identify the pap, afa, and sfa operons in the bacterial chromosomal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/16\">",
"     16",
"    </a>",
"    ]. This has permitted more accurate estimate of the frequency of these adhesins in urinary tract infections.",
"   </p>",
"   <p>",
"    The frequency of the pap, sfa and afa operons is approximately 75, 25, and 10 percent, respectively in pyelonephritis, 45, 20, and 12 percent in cystitis, and 24, 27, and 0 percent in asymptomatic bacteriuria [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/15\">",
"     15",
"    </a>",
"    ]. We have detected at least one adhesin system in virtually all young females with primary pyelonephritis and a normal urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations have led us and other investigators to suggest that patients with UTI who are infected with non-uropathogenic bacteria (ie, without fimbriae) should undergo a uroradiologic evaluation to detect an anatomic abnormality predisposing to infection such as intermittent reflux, neuromuscular dysfunction of the bladder or bladder neck obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The clinical relevance of this suggestion is at present limited since genotypic methods to detect adhesins are restricted to a few specialized laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5514840\">",
"    <span class=\"h2\">",
"     Fimbriae",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to adhesins, which influence the likelihood of infection, fimbriae have other virulence properties. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I fimbriae in E. coli serve as virulence factors by promoting persistence of the infection and by increasing the inflammatory response to the infection [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/19\">",
"       19",
"      </a>",
"      ]. Children who have acute pyelonephritis due to these organisms have been noted to have a more rapid onset of infection, higher fever, longer duration of fever, and a higher white blood cell count than those infected with other organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a murine model of pyelonephritis, Dr fimbriae in E. coli promoted renal tropism and prevented the clearance of infection. This effect was mediated by binding to renal tubular basement membranes and Bowman's capsule via decay accelerating factor (a complement regulatory receptor) and collagen type IV [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/13,15\">",
"       13,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type I fimbriae appear to contribute to the ability of uropathogenic E. coli to impair ureteric contractility, which is thought to be instrumental in limiting ascension of bacteria from the bladder to kidneys [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of fimbriae has potentially important therapeutic implications for prevention of urinary tract infections. In a murine model, for example, animals vaccinated against the FimH adhesin developed antibodies that inhibited E. coli binding to human bladder cells in vitro and reduced colonization of the bladder mucosa by more than 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/26\">",
"     26",
"    </a>",
"    ]. The latter effect was associated with IgG anti-FimH antibodies in the urine. Passive immunization with sera from these animals also prevented colonization.",
"   </p>",
"   <p>",
"    The two most successful vaccine formulations thus far include a daily oral capsule containing membrane proteins from 18 E. coli strains and a vaginal suppository containing ten heat-killed uropathogenic E. coli strains; however, they require frequent administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/27\">",
"     27",
"    </a>",
"    ]. These are both available in Switzerland. There are no vaccines against uropathogenic E. coli licensed in the United States. Research towards their development is ongoing. &nbsp;",
"   </p>",
"   <p>",
"    It is likely that antibiotic prophylaxis of recurrent UTI with low (non-bactericidal) dose antibiotics reduces the frequency of relapses through diminished fimbrial adhesion to the urothelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional factors also affect the virulence of E. coli [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/10\">",
"     10",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of flagellae, which are necessary for motility.",
"     </li>",
"     <li>",
"      Production of a hemolysin, which induces formation of pores in the cell membrane, and aerobactin, a siderophore necessary for iron uptake in the iron-poor environment of the urinary tract.",
"     </li>",
"     <li>",
"      Resistance to plasma bactericidal properties.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17016903\">",
"    <span class=\"h2\">",
"     Entry into urothelial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uropathogenic E. coli (UPEC) are able to invade urothelial cells to replicate within them [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/6\">",
"     6",
"    </a>",
"    ]. Entry into bladder epithelial cells provides UPEC with a protected niche where the bacteria can persist, quiescent, for long periods, unperturbed by host defenses and protected from antibiotic therapy. These reservoirs likely serve as sources of seemingly recurrent infections [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROTEUS MIRABILIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteus mirabilis is armed with various virulence factors, including the production of hemolysin and IgA protease, iron acquisition, flagella, fimbriae and, most importantly, the secretion of urease (",
"    <a class=\"graphic graphic_figure graphicRef87632 \" href=\"UTD.htm?26/18/26920\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/30\">",
"     30",
"    </a>",
"    ]. Urease is a high molecular weight cytoplasmic enzyme that hydrolyzes urea to ammonia and carbon dioxide. Ammonia combines with hydrogen to form ammonium; the ensuing reduction in free hydrogen ion concentration leads to alkalinization with the urine pH being well above 7.0 and sometimes as high as 9.0.",
"   </p>",
"   <p>",
"    The alkaline urine promotes the precipitation of phosphate, carbonate and magnesium, leading to the formation of struvite stones that often form large staghorn calculi. These stones contain a mixture of a proteinaceous matrix, leukocytes, struvite and bacteria. This process is self-perpetuating since the Proteus-contaminated stone is a permanent source of bacteria. In addition, its presence within the urinary tract leads to urinary stasis, which promotes further bacterial multiplication, urinary alkalinization, and the deposition of new layers of struvite. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In terms of bacterial adhesion, P. mirabilis produces at least four types of fimbriae that do not appear to be absolutely required for the induction of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/30\">",
"     30",
"    </a>",
"    ]. At least two fimbrial systems may contribute to urinary tract colonization: the",
"    <span class=\"nowrap\">",
"     MR/P",
"    </span>",
"    fimbriae for bladder and kidney infection; and the PMF fimbriae for bladder infection.",
"   </p>",
"   <p>",
"    The acquisition of a particular phenotype known as \"swarm cell differentiation\" that facilitates P. mirabilis ascent into the urinary tract has also been identified as a factor in uropathogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/31\">",
"     31",
"    </a>",
"    ]. It is characterized by the formation of very long flagellae. Mice inoculated with wild type Proteus strains that are endowed with the \"swarm\" phenotype have a higher mortality rate than those inoculated with vegetative strains. Bladder inoculation with the \"swarm\" type of Proteus significantly increases the incidence of pyelonephritis. The relevance of this phenomenon in human UTI remains to be determined.",
"   </p>",
"   <p>",
"    Studies of vaccination with Proteus fimbrial proteins have been conducted in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/32\">",
"     32",
"    </a>",
"    ]. As an example, intranasal immunization with the N-terminal domain of the tip adhesin of",
"    <span class=\"nowrap\">",
"     MR/P",
"    </span>",
"    fimbriae was effective in preventing P. mirabilis urinary tract infection in mice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     STAPHYLOCOCCUS SAPROPHYTICUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus saprophyticus is a common cause of UTI, particularly cystitis in young, sexually active women [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. It is also an infrequent cause of acute pyelonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]. S. saprophyticus adheres strongly to the urothelium, a process that appears to be linked to a lactosamine residue [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16102/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5514776\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adhesion onto mucosal or urothelial cells is an important phenomenon determining bacterial virulence of uropathogenic Enterobacteriaceae and relies upon the presence fimbriae or other surface adhesion systems (",
"      <a class=\"graphic graphic_figure graphicRef87632 \" href=\"UTD.htm?26/18/26920\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In Escherichia coli, adhesins that are located on the tip of bacterial fimbriae or on the bacterial surface itself bind to target sites on host cells and help mediate uropathogenicity (",
"      <a class=\"graphic graphic_table graphicRef55155 \" href=\"UTD.htm?36/19/37179\">",
"       table 1",
"      </a>",
"      ). Virtually all cases of E. coli pyelonephritis in young women with a normal urinary tract are caused by isolates that possess at least one adhesin system. The fimbriae themselves also contribute to virulence through other mechanisms and are an attractive target for vaccination strategies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Escherichia coli'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The secretion of urease by Proteus mirabilis is an important virulence factor that leads to alkalinization of the urine and formation of stones that contain a proteinaceous matrix, leukocytes, struvite, and bacteria. These stones are a permanent source of bacteria. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Proteus mirabilis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/1\">",
"      Schoolrik GK. How Escherichia coli infects the urinary tract. N Engl J Med 1989; 320:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/2\">",
"      Svanborg Ed&eacute;n C, Hausson S, Jodal U, et al. Host-parasite interaction in the urinary tract. J Infect Dis 1988; 157:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/3\">",
"      Roberts JA. Etiology and pathophysiology of pyelonephritis. Am J Kidney Dis 1991; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/4\">",
"      Roberts JA. Bacterial adherence and urinary tract infection. South Med J 1987; 80:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/5\">",
"      Oelschlaeger TA, Dobrindt U, Hacker J. Virulence factors of uropathogens. Curr Opin Urol 2002; 12:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/6\">",
"      Mulvey MA. Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 2002; 4:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/7\">",
"      Roberts JA, Fussell EN, Kaack MB. Bacterial adherence to urethral catheters. J Urol 1990; 144:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/8\">",
"      Reid G, van der Mei HC, Tieszer C, Busscher HJ. Uropathogenic Escherichia coli adhere to urinary catheters without using fimbriae. FEMS Immunol Med Microbiol 1996; 16:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/9\">",
"      Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/10\">",
"      Johnson JR. Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 1991; 4:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/11\">",
"      Johnson JR, Roberts PL, Stamm WE. P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients' characteristics. J Infect Dis 1987; 156:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/12\">",
"      Foxman B, Manning SD, Tallman P, et al. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am J Epidemiol 2002; 156:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/13\">",
"      Servin AL. Pathogenesis of Afa/Dr diffusely adhering Escherichia coli. Clin Microbiol Rev 2005; 18:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/14\">",
"      Lane MC, Mobley HL. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int 2007; 72:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/15\">",
"      Le Bougu&eacute;nec C, Lalioui L, du Merle L, et al. Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. J Clin Microbiol 2001; 39:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/16\">",
"      Le Bouguenec C, Archambaud M, Labigne A. Rapid and specific detection of the pap, afa, and sfa adhesin-encoding operons in uropathogenic Escherichia coli strains by polymerase chain reaction. J Clin Microbiol 1992; 30:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/17\">",
"      Kuehn MJ, Heuser J, Normark S, Hultgren SJ. P pili in uropathogenic E. coli are composite fibres with distinct fibrillar adhesive tips. Nature 1992; 356:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/18\">",
"      Stapleton A, Nudelman E, Clausen H, et al. Binding of uropathogenic Escherichia coli R45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest 1992; 90:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/19\">",
"      Goluszko P, Moseley SL, Truong LD, et al. Development of experimental model of chronic pyelonephritis with Escherichia coli O75:K5:H-bearing Dr fimbriae: mutation in the dra region prevented tubulointerstitial nephritis. J Clin Invest 1997; 99:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/20\">",
"      Valle J, Mabbett AN, Ulett GC, et al. UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli. J Bacteriol 2008; 190:4147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/21\">",
"      Meyrier A, Condamin MC, Fernet M, et al. Frequency of development of early cortical scarring in acute primary pyelonephritis. Kidney Int 1989; 35:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/22\">",
"      Connell I, Agace W, Klemm P, et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 1996; 93:9827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/23\">",
"      Hanson LA. Prognostic indicators in childhood urinary infections. Kidney Int 1982; 21:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/24\">",
"      Floyd RV, Upton M, Hultgren SJ, et al. Escherichia coli-mediated impairment of ureteric contractility is uropathogenic E. coli specific. J Infect Dis 2012; 206:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/25\">",
"      Nicolle LE. Terra incognito: the ureter in urinary tract infection. J Infect Dis 2012; 206:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/26\">",
"      Langermann S, Palaszynski S, Barnhart M, et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 1997; 276:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/27\">",
"      Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 2010; 78:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/28\">",
"      Dhakal BK, Kulesus RR, Mulvey MA. Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli. Eur J Clin Invest 2008; 38 Suppl 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/29\">",
"      Schulz WA. Uropathogenic bacteria leave a mark. Lab Invest 2011; 91:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/30\">",
"      Mobley HL, Island MD, Massad G. Virulence determinants of uropathogenic Escherichia coli and Proteus mirabilis. Kidney Int Suppl 1994; 47:S129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/31\">",
"      Allison C, Em&ouml;dy L, Coleman N, Hughes C. The role of swarm cell differentiation and multicellular migration in the uropathogenicity of Proteus mirabilis. J Infect Dis 1994; 169:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/32\">",
"      Li X, Lockatell CV, Johnson DE, et al. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infect Immun 2004; 72:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/33\">",
"      Latham RH, Running K, Stamm WE. Urinary tract infections in young adult women caused by Staphylococcus saprophyticus. JAMA 1983; 250:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/34\">",
"      Hovelius B, M&aring;rdh PA. Staphylococcus saprophyticus as a common cause of urinary tract infections. Rev Infect Dis 1984; 6:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16102/abstract/35\">",
"      Jordan PA, Iravani A, Richard GA, Baer H. Urinary tract infection caused by Staphylococcus saprophyticus. J Infect Dis 1980; 142:510.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8055 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16102=[""].join("\n");
var outline_f15_46_16102=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5514776\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ESCHERICHIA COLI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adhesins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5514840\">",
"      Fimbriae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other virulence factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17016903\">",
"      Entry into urothelial cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROTEUS MIRABILIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      STAPHYLOCOCCUS SAPROPHYTICUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5514776\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8055\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8055|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/18/26920\" title=\"figure 1\">",
"      Overview of uropathogen virulence factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8055|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/32/29184\" title=\"picture 1\">",
"      Uropathogenic E coli adhesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8055|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/19/37179\" title=\"table 1\">",
"      E coli adhesins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16103="Enzalutamide: Drug information";
var content_f15_46_16103=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Enzalutamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/25/34196?source=see_link\">",
"    see \"Enzalutamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15036121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xtandi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14957252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiandrogen;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antiandrogen",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15036220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prostate cancer, metastatic, castration-resistant:",
"     </b>",
"     Oral: 160 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant strong CYP2C8 inhibitors:",
"     </b>",
"     Avoid concomitant use if possible. If coadministration is necessary, reduce enzalutamide dose to 80 mg once daily. If the strong CYP2C8 inhibitor is discontinued, adjust the enzalutamide dose back up to the dose used prior to the initiation of the inhibitor.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15036230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15036231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing mild-to-moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-89 mL/minute): No initial dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute), including end-stage renal disease: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15036232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pre-existing severe impairment (Child-Pugh class C): No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15036233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If &ge;grade 3 toxicity occurs, withhold treatment for 1 week or until symptom(s) improve to &le;grade 2, then resume at same dose, or reduce dose to 120 mg or 80 mg once daily, if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Seizures: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15038959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xtandi&reg;: 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15036122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15036241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food; take at the same time each day. Swallow capsules whole; do not chew, dissolve, or open the capsules.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:0em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14957254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of metastatic, castration-resistant prostate cancer in patients previously treated with docetaxel",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15036113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enzalutamide may be confused with bicalutamide, flutamide, nilutamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Xtandi&reg; may be confused with Jevtana&reg;, Xgeva&reg;, Zometa&reg;, Zytiga&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14974979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (51%), headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flashes (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (15%; grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (26%), arthralgia (21%), musculoskeletal pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), insomnia (9%), anxiety (7%), hypoesthesia (4%), mental impairment (4%), hallucinations (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin (4%), pruritus (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Hematuria (7%), pollakiuria (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness (10%), paresthesia (7%), falling (5%), fractures (4%), stiffness (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Lower respiratory tract infection (9%), epistaxis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (&le;6%; including sepsis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Seizures",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15036133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15036145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Seizures were observed in a clinical trial (onset: ~1-20 months after treatment initiation). Therapy was permanently discontinued and patients were not rechallenged; seizures resolved upon therapy cessation. Patients with predisposing factors for seizure were excluded from the trial; factors include seizure history, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation, or the use of concomitant medications which may lower the seizure threshold. Enzalutamide should be used with caution in patients with a history of seizure disorders or other predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Spermatogenesis: May cause hypospermatogenesis; may impair male fertility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Enzalutamide is a strong CYP3A4 and moderate CYP2C9 and CYP2C19 inducer; avoid concomitant use with narrow therapeutic index medications metabolized by CYP3A4, CYP2C9, and CYP2C19. If possible, avoid concomitant administration with moderate and strong CYP3A4 inducers (may reduce enzalutamide plasma concentrations). Avoid coadministration with strong CYP2C8 inhibitors; if concomitant use is necessary, reduce enzalutamide dose. Avoid coadministration with strong and moderate CYP2C8 inducers. If concomitant administration with warfarin cannot be avoided, additional INR monitoring is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15163878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C8 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2C19 (weak/moderate), CYP2C9 (weak/moderate), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15163876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Enzalutamide may decrease the serum concentration of Alfentanil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Enzalutamide may decrease the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May increase the serum concentration of Enzalutamide. Management: Avoid concurrent use of strong CYP2C8 inhibitors and enzalutamide if possible. If the combination must be used, reduce enzalutamide to 80 mg once daily.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Enzalutamide may decrease the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Enzalutamide may decrease the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Enzalutamide may decrease the serum concentration of FentaNYL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: Enzalutamide may decrease the serum concentration of Fosphenytoin-Phenytoin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Enzalutamide may decrease the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Enzalutamide may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Enzalutamide may decrease the serum concentration of Sirolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Enzalutamide may decrease the serum concentration of Tacrolimus (Systemic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Enzalutamide may decrease the serum concentration of Warfarin. More specifically, enzalutamide may decrease concentrations of the S-warfarin enantiomer.  Management: Avoid concurrent use of warfarin and enzalutamide whenever possible.  If the combination must be used, conduct additional INR monitoring as serum concentrations may be decreased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15036124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15036125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enzalutamide is an androgen receptor inhibitor. Although animal reproduction studies have not been conducted, it is expected to cause fetal harm based on its mechanism of action. Enzalutamide is not indicated for use in women and is specifically contraindicated for use in women who are or may become pregnant. Men using this medication should use a condom if having intercourse with a pregnant woman. A condom plus another effective method of birth control is recommended during therapy and for 3 months after treatment for men using this medication and who are having intercourse with a woman of reproductive potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15036131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15036132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enzalutamide is not indicated for use in women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F15036240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Xtandi Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (120): $8940.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15036243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for signs/symptoms of seizure, loss of consciousness, dizziness, and hallucinations; CBC with differential and liver function tests (baseline and periodic); additional INR monitoring (if on warfarin)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15036165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enzalutamide is a pure androgen receptor signaling inhibitor; unlike other antiandrogen therapies, it has no known agonistic properties. It inhibits androgen receptor nuclear translocation, DNA binding, and coactivator mobilization, leading to cellular apoptosis and decreased prostate tumor volume.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15036167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 110 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Parent drug: 97% to 98% to primarily albumin; active metabolite: 95% to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic via CYP2C8 (responsible for formation of active metabolite N-desmethyl enzalutamide) and CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 5.8 days (range: 2.8-10.2 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: 1 hour (range: 0.5-3 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (71%); feces (14%); primarily as inactive metabolite",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baskin-Bey ES, Shore ND, Barber K, et al, &ldquo;TERRAIN: A Randomized, Double-Blind, Phase II Study Comparing MDV3100 With Bicalutamide (Bic) in Men With Metastatic Castrate-Resistant Prostate Cancer (CRPC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(Suppl): TPS4698 [abstract TPS4698 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Higano CS, Beer TM, Taplin M, et al, &ldquo;Antitumor Activity of MDV3100 in Pre- and Post-Docetaxel Advanced Prostate Cancer: Long-Term Follow-Up of a Phase I/II Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(Suppl): 134 [abstract 134 from 2011 Genitourinary Cancers Symposium].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D'Amico AV, Berger P, et al, \"Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121(6):833-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16103/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montgomery RB, Joshua A, Hannah AL, et al, \"A Randomized, Open-Label, Phase II Study of MDV3100 Alone or in Combination With Leuprolide and Dutasteride as Neoadjuvant Therapy to Prostatectomy in Intermediate and High-Risk Prostate Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(Suppl): TPS4695 [abstract TPS4695 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mukherji D, Eichholz A, and De Bono JS, \"Management of Metastatic Castration-Resistant Prostate Cancer: Recent Advances,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2012, 72(8):1011-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16103/abstract-text/22621691/pubmed\" id=\"22621691\" target=\"_blank\">",
"        22621691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scher HI, Beer TM, Higano CS, et al, \"Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase 1-2 Study,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2010, 375(9724):1437-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16103/abstract-text/20398925/pubmed\" id=\"20398925\" target=\"_blank\">",
"        20398925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scher HI, Fizazi K, Saad F, et al, \"Increased Survival With Enzalutamide in Prostate Cancer After Chemotherapy,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(13):1187-977.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16103/abstract-text/22894553/pubmed\" id=\"22894553\" target=\"_blank\">",
"        22894553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schweizer MT and Antonarakis ES, \"Abiraterone and Other Novel Androgen-Directed Strategies for the Treatment of Prostate Cancer: A New Era of Hormonal Therapies Is Born,\"",
"      <i>",
"       Ther Adv Urol",
"      </i>",
"      , 2012, 4(4):167-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16103/abstract-text/22852027/pubmed\" id=\"22852027\" target=\"_blank\">",
"        22852027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86370 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.97.94.19-BA627EFD15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16103=[""].join("\n");
var outline_f15_46_16103=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036121\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957252\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036220\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036230\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036231\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036232\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036233\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15038959\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036122\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036241\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14957254\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036113\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14974979\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036133\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036145\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163878\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15163876\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036124\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036125\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036131\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036132\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036240\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570452\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036243\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036165\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15036167\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86370\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86370|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/25/34196?source=related_link\">",
"      Enzalutamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16104="Oxcarbazepine: Pediatric drug information";
var content_f15_46_16104=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxcarbazepine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"    see \"Oxcarbazepine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/38/39525?source=see_link\">",
"    see \"Oxcarbazepine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F204790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Oxtellar XR&trade;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F204791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Oxcarbazepine&reg;;",
"     </li>",
"     <li>",
"      Trileptal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Not approved for use; limited information is available.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"      see \"Oxcarbazepine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Oral suspension and tablets are interchangeable on a mg per mg basis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;2 years: Not approved for use; limited information is available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunctive therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2 to &lt;4 years: Initial dose: 8-10 mg/kg/day given in 2 divided doses (usual maximum: 600 mg/day); for children &lt;20 kg, consider initial dose of 16-20 mg/kg/day given in 2 divided doses; increase dose slowly over 2-4 weeks; do not exceed 60 mg/kg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-16 years: Initial dose: 8-10 mg/kg/day given in 2 divided doses (usual maximum: 600 mg/day); increase dose slowly over 2 weeks to the following weight-dependent target maintenance dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     20-29 kg: 900 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     29.1-39 kg: 1200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;39 kg: 1800 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Use of these pediatric target maintenance doses in one clinical trial resulted in doses ranging from 6-51 mg/kg/day (median dose: 31 mg/kg/day) in children 4-16 years of age (Glauser, 2000). In children 2-4 years of age, 50% of patients were titrated to a final dose of at least 55 mg/kg/day with target dose of 60 mg/kg/day. Due to a higher drug clearance, children 2 to &lt;4 years of age may require up to twice the dose per body weight compared to adults; children 4  to &le;12 years of age may require a 50% higher dose per body weight compared to adults (see product information).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 4-16 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion to monotherapy: Initial: 8-10 mg/kg/day given in 2 divided doses, with a simultaneous initial reduction of the dose of concomitant antiepileptic drugs (AEDs); withdraw concomitant AEDs completely over 3-6 weeks, while increasing oxcarbazepine dose as needed by no more than 10 mg/kg/day at approximately weekly intervals; increase oxcarbazepine dose to achieve the recommended monotherapy maintenance dose by weight listed below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initiation of monotherapy: Initial: 8-10 mg/kg/day given in 2 divided doses; increase dose every third day by 5 mg/kg/day to achieve the recommended monotherapy maintenance dose by weight, as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20 kg: 600-900 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     25-30 kg: 900-1200 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     35-40 kg: 900-1500 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     45 kg: 1200-1500 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     50-55 kg: 1200-1800 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     60-65 kg: 1200-2100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     70 kg: 1500-2100 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunctive therapy: Initial: 300 mg twice daily; increase if needed by no more than 600 mg/day at approximately weekly intervals; recommended maintenance dose: 600 mg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Doses &gt;1200 mg/day may have greater efficacy, but most patients are not able to tolerate 2400 mg/day (mostly due to CNS effects); monitor patient closely and measure concentrations of concomitant antiepileptic agents during dosage titration and especially with oxcarbazepine doses &gt;1200 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Conversion to monotherapy: Initial: 300 mg twice daily with a simultaneous initial reduction of the dose of concomitant antiepileptic drugs (AEDs); withdraw concomitant AEDs completely over 3-6 weeks, while increasing oxcarbazepine dose as needed by no more than 600 mg/day at approximately weekly intervals; recommended oxcarbazepine dose (1200 mg twice daily) should be reached in about 2-4 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     A lower dose (1200 mg/day) was effective in one study in patients who initiated oxcarbazepine monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initiation of monotherapy: Initial: 300 mg twice daily; increase by 300 mg/day every third day to 1200 mg/day; a higher dose (2400 mg/day) was effective in patients who were converted from other AEDs to oxcarbazepine monotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Initial dose: Administer 50% of the normal starting dose; slowly increase the dose if needed, using a slower dosage titration than normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate hepatic impairment: No dosage adjustment recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Not evaluated",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 300 mg/5 mL (250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trileptal&reg;: 300 mg/5 mL (250 mL) [contains ethanol, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 150 mg, 300 mg, 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trileptal&reg;: 150 mg, 300 mg, 600 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oxtellar XR&trade;: 150 mg, 300 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12617171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Trileptal&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM246799.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Oxtellar XR&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM326087.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: May be taken without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Prior to using for the first time, firmly insert the manufacturer supplied plastic adapter into the neck of the bottle; cover the adapter with child-resistant cap when not in use; shake suspension well (for at least 10 seconds) before use; remove child-resistant cap and insert manufacturer supplied oral syringe to withdraw appropriate dose; dose may be administered directly from syringe or mixed in a small amount of water immediately prior to use; after use, rinse oral syringe with warm water and allow to dry thoroughly; discard any unused portion 7 weeks after first opening bottle",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature (25&deg;C); dispense in tight container; suspension is stable for 7 weeks after first opening the bottle",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of partial seizures in patients with epilepsy (FDA approved as monotherapy in ages &ge;4 years and adults; FDA approved as adjunctive therapy in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6224110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       OXcarbazepine may be confused with carBAMazepine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Trileptal&reg; may be confused with TriLipix&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported in adults with doses of up to 2400 mg/day (includes patients on monotherapy, adjunctive therapy, and those not previously on AEDs); incidence in children was similar.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension, leg edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal feelings, abnormal thinking, agitation, amnesia, ataxia, confusion, dizziness, EEG abnormalities, fatigue, fever. headache, insomnia, nervousness, somnolence, speech disorder, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, gastritis, nausea, taste perversion, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal coordination, abnormal gait, back pain, dysmetria, falling down, muscle weakness, sprains/strains, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Abnormal accommodation, abnormal vision, diplopia, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Chest  infection, epistaxis, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggressive reaction, alopecia, amylase increased, anaphylaxis, angioedema, anxiety, aphasia, aplastic anemia, biliary pain, bradycardia, bruising, cardiac failure, cerebral hemorrhage, chest pain, cholelithiasis, colitis, conjunctival hemorrhage, consciousness decreased, convulsions aggravated, delirium, delusion, dysphagia, dysphonia, dyspnea, dystonia, dysuria, emotional lability, enteritis, erythema multiforme, erythematosus rash, esophagitis, eye edema, extrapyramidal disorder, GGT increased, gingival bleeding, gingival hyperplasia, hematuria, hemianopia, hemiplegia, hematemesis, hypersensitivity reaction, hypertension, hypocalcemia, hypochondrium pain, hypoesthesia, hypokalemia, hysteria, laryngismus, leukopenia, leukorrhea, lipase increased, liver enzymes elevated, maculopapular rash, manic reaction, multiorgan hypersensitivity (eosinophilia, arthralgia, rash, fever, lymphadenopathy), muscle contractions (involuntary), mydriasis, neuralgia, oculogyric crisis, orthostatic hypotension, palpitation, pancreatitis, pancytopenia, panic disorder, paralysis, paroniria, photophobia, photosensitivity reaction, pleurisy, priapism, purpura, psychosis, ptosis, renal pain, rigors, scotoma, sialoadenitis, Stevens-Johnson syndrome, stupor, suicidal behavior/ideation, syncope, systemic lupus erythematosus, tachycardia, tetany, thrombocytopenia, toxic epidermal necrolysis, ulcerative stomatitis, urinary tract pain, urticaria, vitiligo, weight loss, xerophthalmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxcarbazepine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CNS adverse effects may occur, including somnolence (children: ~35%), fatigue, coordination abnormalities [ataxia and gait disturbances (children: 23%)], and cognitive symptoms (difficulty concentrating, speech or language problems, and psychomotor slowing); these effects may be more common when oxcarbazepine is used as add-on therapy versus monotherapy. Use with caution and modify dose in patients with renal impairment. Multiple drug interactions may occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Significant hyponatremia may occur; a serum sodium &lt;125 mEq/L has been reported in 2.5% of patients; usually occurs within first 3 months of therapy but has been reported in patients &gt;1 year after initiation; consider monitoring serum sodium especially in patients who receive other drugs that may cause hyponatremia and in patients with symptoms of hyponatremia (eg, nausea, headache, malaise, confusion, lethargy, obtundation, or an increase in seizure frequency or severity); dosage reduction or fluid restriction may be beneficial. Do not abruptly discontinue therapy, withdraw gradually to lessen chance for increased seizure frequency (unless a more rapid withdrawal is required due to safety concerns). Serious dermatologic reactions (including potentially fatal Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported (median onset 19 days); consider discontinuation of oxcarbazepine and alternative therapy in patients who develop skin reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Rare cases of angioedema have been reported after the first or subsequent doses of oxcarbazepine; angioedema has occurred in the lips, eyelids, glottis, and larynx; angioedema of the larynx (laryngeal edema) can be fatal; permanently discontinue oxcarbazepine if any of these reactions occur; do not rechallenge or restart oxcarbazepine in these patients. Rare cases of anaphylaxis and  multiorgan hypersensitivity reaction with rash, lymphadenopathy, fever, abnormal liver function tests, hepatitis, nephritis, oliguria, hepatorenal syndrome, hematological abnormalities, pruritus, asthenia, and/or arthralgia have also been reported; median time to detection: 13 days post-therapy initiation; permanently discontinue oxcarbazepine if any of these reactions occur; do not rechallenge or restart oxcarbazepine in these patients. Cross-hypersensitivity reactions with carbamazepine may occur (incidence: 25% to 30%).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiepileptic drugs (AEDs) increase the risk of suicidal behavior and ideation in patients receiving these medications for any indication. Pooled analyses of placebo-controlled trials involving 11 different AEDs (regardless of indication) showed a twofold increased risk of suicidal thoughts or behavior (estimated incidence rate: 0.43% in AED treated patients compared to 0.24% of patients receiving placebo); increased risk was observed as early as 1 week after initiation of AED and continued through duration of trials (most trials &le;24 weeks); risk did not vary significantly by age (age range: 5&ndash;100 years). Consider risks and benefits of AEDs before prescribing. Monitor all patients receiving an AED for emergence of suicidal thoughts or behavior, thoughts of self-harm, any unusual changes in behavior or mood, or the emergence or worsening of depressive symptoms; notify healthcare provider immediately if symptoms or concerning behavior occur.",
"     <b>",
"      Note:",
"     </b>",
"     The FDA is requiring that a Medication Guide be developed for all antiepileptic drugs informing patients of this risk.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: OXcarbazepine may decrease the serum concentration of Cobicistat.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): OXcarbazepine may decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): OXcarbazepine may decrease the serum concentration of Contraceptives (Progestins).  Management: Contraceptive failure is possible.  Use of an additional or alternative, nonhormonal method of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: OXcarbazepine may decrease the serum concentration of Elvitegravir.  Management: Consider using an alternative antiepileptic when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin-Phenytoin: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of Fosphenytoin-Phenytoin. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine.  Management: Consider alternatives to nifedipine for patients who are using strong CYP3A4 inducers.  At least one specific brand of nifedipine (Adalat CC) lists this combination as contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: OXcarbazepine may decrease the serum concentration of Perampanel. Perampanel may increase the serum concentration of OXcarbazepine.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used with oxcarbazepine.  Patients receiving this combination should be followed closely for response, especially with any changes to oxcarbazepine therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: May decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. OXcarbazepine may increase the serum concentration of PHENobarbital. Management: Consider increasing the initial adult oxcarbazepine extended release tablet (Oxtellar XR) dose to 900 mg/day. No specific recommendations are available for other oxcarbazepine formulations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: OXcarbazepine may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: OXcarbazepine may enhance the serotonergic effect of Selegiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the serum concentration of OXcarbazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablets: Food does not affect rate or extent of absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension: Effect of food has not been studied, but bioavailability is not likely to be affected",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies oxcarbazepine as pregnancy category C. Oxcarbazepine, the active metabolite MHD and the inactive metabolite DHD, crosses the placenta and can be detected in the newborn. An increased risk in the overall rate of major congenital malformations has not been observed following maternal use of oxcarbazepine. Available studies have not been large enough to determine if there is an increased risk of specific defects. In general, the risk of teratogenic effects is higher with AED polytherapy than monotherapy. Plasma concentrations of MHD gradually decrease due to physiologic changes which occur during pregnancy; patients should be monitored during pregnancy and postpartum. Oxcarbazepine may decrease plasma concentrations of hormonal contraceptives.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to oxcarbazepine during pregnancy are encouraged to enroll themselves into the AED Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seizure frequency, duration and severity; symptoms of CNS depression (dizziness, headache, somnolence) and allergic reaction; consider monitoring serum sodium (particularly during first three months of therapy) especially in patients who receive other drugs that may cause hyponatremia and in patients with symptoms of hyponatremia; signs and symptoms of suicidality (eg, anxiety, depression, behavior changes)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Active 10-monohydroxy metabolite (MHD) is primarily responsible for anticonvulsant activity; exact mechanism unknown; both MHD and oxcarbazepine are thought to decrease the spread of seizure activity by blockade of sodium channels; also increases conductance of potassium and modulates activity of high-voltage activated calcium channels",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: MHD: V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): Adults: 49 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Oxcarbazepine: 67%; MHD: 40%, primarily to albumin; parent drug and metabolite do not bind to alpha-1 acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Oxcarbazepine is extensively metabolized in the liver to its active 10-monohydroxy metabolite (MHD); MHD undergoes further metabolism via glucuronide conjugation; 4% of dose is oxidized to the 10,11-dihydroxy metabolite (DHD) (inactive); 70% of serum concentration appears as MHD, 2% as unchanged oxcarbazepine, and the rest as minor metabolites;",
"     <b>",
"      Note:",
"     </b>",
"     Unlike carbamazepine, autoinduction of metabolism has not been observed and biotransformation of oxcarbazepine does not result in an epoxide metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablets and suspension have similar bioavailability (based on MDH serum concentrations)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oxcarbazepine: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     MHD: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): MHD: 19 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablets: 3-13 hours (median: 4.5 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: Median: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &gt;95% of dose is excreted in the urine with &lt;1% as unchanged parent drug, 27% as unchanged MHD, 49% as MHD glucuronides, 3% as DHD (inactive), and 13% as conjugate of oxcarbazepine and MHD; &lt;4% excreted in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance (per body weight):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2 to &lt;4 years: Increased by &sim;80% compared to adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-12 years: Increased by &sim;40% compared to adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;13 years: Values approach adult clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic impairment: Mild to moderate: No effect on pharmacokinetics; Severe: Not studied",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/38/39525?source=see_link\">",
"      see \"Oxcarbazepine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inform prescriber if allergic to carbamazepine. Severe allergic reactions (anaphylaxis) or swelling of the face, lips, eyes, tongue, or difficulty in swallowing or breathing may occur rarely after taking oxcarbazepine; report these reactions to physician immediately; stop taking oxcarbazepine until physician can be consulted. Report excessive somnolence or allergic reactions to physician immediately; report unusual symptoms such as nausea, headache, malaise, confusion, lethargy, obtundation, worsening of seizure activity, or loss of seizure control to physician immediately (blood test for serum sodium may be needed); report skin rash, fever, itching, joint pain, abdominal pain, lack of urination, and swollen glands to physician immediately (these may be signs of a serious or potentially fatal multiorgan hypersensitivity reaction). Antiepileptic agents may increase the risk of suicidal thoughts and behavior; notify physician if you feel more depressed or have thoughts of suicide or self-harm.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Avoid alcohol. Oxcarbazepine may decrease the effectiveness of oral contraceptives (use an alternative, nonhormonal, form of contraception). Do not abruptly discontinue (an increase in seizure activity may result).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms of overdose may include CNS depression (somnolence, ataxia, obtundation); treatment is symptomatic and supportive; consider general poisoning management (eg, gastric lavage, activated charcoal); largest reported overdose is 24 g; oxcarbazepine is a keto analogue of carbamazepine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Glauser TA, Nigro M, Sachdeo R, et al, &ldquo;Adjunctive Therapy With Oxcarbazepine in Children With Partial Seizures. The Oxcarbazepine Pediatric Study Group,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2000, 54(12):2237-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16104/abstract-text/10881246/pubmed\" id=\"10881246\" target=\"_blank\">",
"        10881246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tecoma ES, &ldquo;Oxcarbazepine,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1999, 40(Suppl 5): S37-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16104/abstract-text/10530693 /pubmed\" id=\"10530693 \" target=\"_blank\">",
"        10530693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12664 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-118.97.94.19-A2277D8E11-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16104=[""].join("\n");
var outline_f15_46_16104=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204790\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204791\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054581\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864282\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054574\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204762\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204747\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12617171\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054584\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054577\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054583\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6224110\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204830\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054587\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054573\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054572\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204756\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054590\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204758\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054580\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054571\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054586\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054579\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054588\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=related_link\">",
"      Oxcarbazepine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/38/39525?source=related_link\">",
"      Oxcarbazepine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16105="Diazepam: Drug information";
var content_f15_46_16105=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diazepam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/58/25509?source=see_link\">",
"    see \"Diazepam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"    see \"Diazepam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diastat&reg;;",
"     </li>",
"     <li>",
"      Diastat&reg; AcuDial&trade;;",
"     </li>",
"     <li>",
"      Diazepam Intensol&trade;;",
"     </li>",
"     <li>",
"      Valium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diazepam&reg;;",
"     </li>",
"     <li>",
"      Bio-Diazepam;",
"     </li>",
"     <li>",
"      Diastat&reg;;",
"     </li>",
"     <li>",
"      Diazemuls&reg;;",
"     </li>",
"     <li>",
"      Diazepam Auto Injector;",
"     </li>",
"     <li>",
"      Diazepam Injection USP;",
"     </li>",
"     <li>",
"      Novo-Dipam;",
"     </li>",
"     <li>",
"      PMS-Diazepam;",
"     </li>",
"     <li>",
"      Valium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral absorption is more reliable than I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ethanol withdrawal:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     10 mg 3-4 times during first 24 hours, then decrease to 5 mg 3-4 times/day as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Anticonvulsant (acute treatment):",
"     </b>",
"     <i>",
"      Rectal gel:",
"     </i>",
"     0.2 mg/kg.",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be rounded upward to the next available dose, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/dose; dose may be repeated in 4-12 hours if needed; do not use for more than 5 episodes per month or more than one episode every 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety (symptoms/disorders):",
"     </b>",
"     <i>",
"      Oral, I.M, I.V.:",
"     </i>",
"     2-10 mg 2-4 times/day if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasm:",
"     </b>",
"     <i>",
"      I.V., I.M.:",
"     </i>",
"     Initial: 5-10 mg; then 5-10 mg in 3-4 hours, if necessary. Larger doses may be required if associated with tetanus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation in the ICU patient:",
"     </b>",
"     <i>",
"      I.V.:",
"     </i>",
"     Loading dose: 5-10 mg; Maintenance dose: 0.03-0.1 mg/kg every 30 minutes to 6 hours (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skeletal muscle relaxant (adjunct therapy):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     2-10 mg 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     5-10 mg every 5-10 minutes given over &le;5 mg/minute (maximum dose: 30 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal gel:",
"     </i>",
"     Premonitory/Out-of-hospital treatment: 10 mg once; may repeat once if necessary (K&auml;lvi&auml;inen, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rapid tranquilization of agitated patient",
"     </b>",
"     (administer every 30-60 minutes):",
"     <i>",
"      Oral:",
"     </i>",
"     5-10 mg; average total dose for tranquilization: 20-60 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F159055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"      see \"Diazepam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant (acute treatment):",
"     </b>",
"     <i>",
"      Rectal gel:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;2 years: Safety and efficacy have not been studied",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-5 years: 0.5 mg/kg (maximum dose: 20 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years: 0.3 mg/kg (maximum dose: 20 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be rounded upward to the next available dose, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, and 20 mg/dose; dose may be repeated in 4-12 hours if needed; do not use for more than 5 episodes per month or more than one episode every 5 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conscious sedation for procedures:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: 0.2-0.3 mg/kg (maximum dose: 10 mg) 45-60 minutes prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Adolescents: 5 mg; may repeat with 2.5 mg if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Febrile seizure prophylaxis:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Children: 1 mg/kg/day divided every 8 hours; initiate therapy at first sign of fever and continue for 24 hours after fever is gone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasm associated with tetanus:",
"     </b>",
"     <i>",
"      I.V., I.M.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &gt;30 days and Children &lt;5 years: 1-2 mg/dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;5 years: 5-10 mg/dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation or muscle relaxation or anxiety:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     Children: 0.12-0.8 mg/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      I.M., I.V.:",
"     </i>",
"     Children: 0.04-0.3 mg/kg/dose every 2-4 hours to a maximum of 0.6 mg/kg within an 8-hour period if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity in cerebral palsy (unlabeled use):",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     Dose should be individualized:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &le;5 years: &lt;8.5 kg: 0.5-1 mg at bedtime; 8.5-15 kg: 1-2 mg at bedtime (Mathew, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-16 years: 1.25 mg 3 times daily to 5 mg 4 times daily (Engle, 1966)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Status epilepticus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Infants &gt;30 days and Children: 0.1-0.3 mg/kg (maximum dose: 10 mg) given over &le;5 mg/minute; may repeat dose after 5-10 minutes (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &gt;30 days and Children &lt;5 years: 0.2-0.5 mg given slowly every 2-5 minutes (maximum total dose: 5 mg); repeat in 2-4 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;5 years: 1 mg given slowly every 2-5 minutes (maximum total dose: 10 mg); repeat in 2-4 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Rectal gel:",
"     </i>",
"     0.5 mg/kg/dose then 0.25 mg/kg/dose in 10 minutes if needed (maximum dose: 20 mg) (Hegenbarth, 2008) (prepare dose using parenteral formulation)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Oral absorption is more reliable than I.M.",
"     </b>",
"     Elderly and/or debilitated patients:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 2-2.5 mg 1-2 times/day initially; increase gradually as needed and tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal gel: Due to the increased half-life in elderly and debilitated patients, consider reducing dose.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F159037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No dose adjustment recommended; decrease dose if administered for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Risk of propylene glycol toxicity; monitor closely if using for prolonged periods or at high doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not dialyzable (0% to 5%); supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F159038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease maintenance dose by 50%; half-life significantly prolonged.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [adult rectal tip (6 cm)]: 20 mg (4 mL) [delivers set doses of 12.5 mg, 15 mg, 17.5 mg, 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade;: 20 mg (4 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate; 5 mg/mL (delivers set doses of 12.5 mg, 15 mg, 17.5 mg, and 20 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [pediatric rectal tip (4.4 cm)]: 5 mg/mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg;: 5 mg/mL (0.5 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [pediatric/adult rectal tip (4.4 cm)]: 10 mg (2 mL) [delivers set doses of 5 mg, 7.5 mg, 10 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade;: 10 mg (2 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate; 5 mg/mL (delivers set doses of 5 mg, 7.5 mg, and 10 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 5 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 5 mg/5 mL (5 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diazepam Intensol&trade;: 5 mg/mL (30 mL) [contains ethanol 19%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valium&reg;: 5 mg, 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valium&reg;: 2 mg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F159082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F159006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral solution (Intensol&trade;) should be diluted before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous infusion is not recommended because of precipitation in I.V. fluids and absorption of drug into infusion bags and tubing. In children, do not exceed 1-2 mg/minute IVP; adults 5 mg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal gel: Prior to administration, confirm that prescribed dose is visible and correct, and that the green &ldquo;ready&rdquo; band is visible. Patient should be positioned on side (facing person responsible for monitoring), with top leg bent forward. Insert rectal tip (lubricated) into rectum and push in plunger gently over 3 seconds. Remove tip of rectal syringe after 3 additional seconds. Buttocks should be held together for 3 seconds after removal. Dispose of syringe appropriately.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F159088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per manufacturer, do not mix I.V. product with other medications.",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Dobutamine, fentanyl, methadone, morphine, nafcillin, quinidine gluconate, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, atracurium, bivalirudin, cefepime, dexmedetomidine, diltiazem, doripenem, fenoldopam, fluconazole, foscarnet, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, meropenem, oxaliplatin, pancuronium, pantoprazole, potassium chloride, propofol, tigecycline, tirofiban, vecuronium, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, hydromorphone, remifentanil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, doxapram, glycopyrrolate, heparin, hydromorphone, ketamine, nalbuphine, pantoprazole, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ketorolac, lidocaine, meperidine, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Management of anxiety disorders, ethanol withdrawal symptoms; skeletal muscle relaxant; treatment of convulsive disorders; preoperative or preprocedural sedation and amnesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal gel: Management of selected, refractory epilepsy patients on stable regimens of antiepileptic drugs requiring intermittent use of diazepam to control episodes of increased seizure activity",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F159077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Panic disorders; short-term treatment of spasticity in children with cerebral palsy; sedation for mechanically-ventilated patients in the intensive care unit",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diazepam may be confused with diazoxide, diltiazem, Ditropan, LORazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valium&reg; may be confused with Valcyte&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Adverse reactions may vary by route of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, ataxia, confusion, depression, drowsiness, fatigue, headache, slurred speech, paradoxical reactions (eg, aggressiveness, agitation, anxiety, delusions, hallucinations, inappropriate behavior, increased muscle spasms, insomnia, irritability, psychoses, rage, restlessness, sleep disturbances, stimulation), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, salivation changes (dry mouth or hypersalivation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis, pain with injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, respiratory rate decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); myasthenia gravis; severe respiratory insufficiency; severe hepatic insufficiency; sleep apnea syndrome; acute narrow-angle glaucoma; not for use in children &lt;6 months of age (oral)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric and paradoxical reactions: Reactions, including hyperactive or aggressive behavior, hallucinations, and psychoses, have been reported with benzodiazepines, particularly in adolescent/pediatric or elderly patients. Diazepam should be discontinued if reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Convulsive disorders: When used as an adjunct in treating convulsive disorders, an increase in frequency/severity of grand mal seizures may occur and require dose adjustment of anticonvulsant. Abrupt withdrawal may result in a temporary increase of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use caution in patients with depression or anxiety associated with depression, particularly if suicidal risk may be present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use (generally &gt;10 days).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impaired gag reflex: Use with caution in patients with an impaired gag reflex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease; a lower dose is recommended for chronic respiratory insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4  inhibitors, moderate or strong CYP3A4 and CYP2C19 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Narcotics: The dosage of narcotics should be reduced by approximately one-third when diazepam is added.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated/elderly patients: Use with caution; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects; limit dose to smallest effective amount (2-2.5 mg once or twice daily initially, to be increased gradually and as tolerated) to avoid adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group and slower metabolism of long-acting agents (such as diazepam), avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Safety and efficacy of the injection have not been established in children &lt;1 month of age. Solution for injection may contain sodium benzoate, benzyl alcohol, or benzoic acid. Large amounts have been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obese patients: Use with caution in obese patients; may have prolonged action when discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy of oral use have not been established in children &lt;6 months of age. Safety and efficacy in rectal gel have not been established in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychotic patients: Use of diazepam is not recommended in place of appropriate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral: Acute hypotension, muscle weakness, apnea, and cardiac arrest have occurred with parenteral administration. Acute effects may be more prevalent in patients receiving concurrent barbiturates, narcotics, or ethanol. Appropriate resuscitative equipment and qualified personnel should be available during administration and monitoring. Avoid use of the injection in patients with shock, coma, or acute ethanol intoxication. Intra-arterial injection or extravasation of the parenteral formulation should be avoided. Parenteral formulation contains propylene glycol, which has been associated with toxicity when administered in high dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol: Parenteral formulation contains propylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rectal gel: Administration of rectal gel should only be performed by individuals trained to recognize characteristic seizure activity for which the product is indicated, and capable of monitoring response to determine need for additional medical intervention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F159074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Potential for drug dependency exists. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Diazepam serum concentrations may be decreased if taken with food. Grapefruit juice may increase diazepam serum concentrations. Management: Avoid concurrent use of grapefruit juice. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease diazepam levels. Yohimbe may decrease the effectiveness of diazepam. Kava kava, valerian, and gotu kola may increase CNS depression. Avoid St John's wort, yohimbe, kava kava, valerian, and gotu kola.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in animal studies. In humans, diazepam and its metabolites (N-desmethyldiazepam, temazepam, and oxazepam) cross the placenta. Teratogenic effects have been observed with diazepam; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines (including diazepam).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F159014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diazepam and N-desmethyldiazepam can be found in breast milk; the oxazepam metabolite has also been detected in the urine of a nursing infant. Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines, including diazepam.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Diazepam Intensol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (30 mL): $33.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Device",
"     </b>",
"     (Diazepam Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/2 mL (2 mL): $37.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Diastat AcuDial Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $371.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $371.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Diastat Pediatric Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (1): $312.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Diazepam Rectal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (1): $281.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $334.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $334.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Diazepam Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (2 mL): $10.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Diazepam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (5 mL): $2.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diazepam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $14.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $22.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $39.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Valium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $300.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (500): $2321.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (500): $3917.54",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory, cardiovascular, and mental status; check for orthostasis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Critically-ill mechanically-ventilated patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (Barr, 2013)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F159002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: Diazepam: 0.2-1.5 mcg/mL (SI: 0.7-5.3 micromole/L); N-desmethyldiazepam (nordiazepam): 0.1-0.5 mcg/mL (SI: 0.35-1.8 micromole/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aliseum (IT);",
"     </li>",
"     <li>",
"      Anlin (TW);",
"     </li>",
"     <li>",
"      Ansiolin (IT);",
"     </li>",
"     <li>",
"      Antenex (AU);",
"     </li>",
"     <li>",
"      Apaurin (HR);",
"     </li>",
"     <li>",
"      Apo-diazepam (CZ);",
"     </li>",
"     <li>",
"      Apozepam (DK);",
"     </li>",
"     <li>",
"      Assival (IL);",
"     </li>",
"     <li>",
"      Azepan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Benzopin (ZA);",
"     </li>",
"     <li>",
"      Calmpose (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cercine (JP);",
"     </li>",
"     <li>",
"      Ceregulart (JP);",
"     </li>",
"     <li>",
"      Compaz (BR);",
"     </li>",
"     <li>",
"      Condition (JP);",
"     </li>",
"     <li>",
"      D-Pam (NZ);",
"     </li>",
"     <li>",
"      Dialag (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Diapam (FI, TR);",
"     </li>",
"     <li>",
"      Diapine (MY, SG, TH, TW);",
"     </li>",
"     <li>",
"      Diapo (MY);",
"     </li>",
"     <li>",
"      Diazem (TR);",
"     </li>",
"     <li>",
"      Diazemuls (GB, IT);",
"     </li>",
"     <li>",
"      Diazepam (HK);",
"     </li>",
"     <li>",
"      Diazepam Desitin (HU);",
"     </li>",
"     <li>",
"      Diazepam-Eurogenerics (LU);",
"     </li>",
"     <li>",
"      Diazepam-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Diazepan (AE, BF, BH, BJ, CI, CY, EG, ES, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Dipezona (AR);",
"     </li>",
"     <li>",
"      Doval (ZA);",
"     </li>",
"     <li>",
"      Dupin (TW);",
"     </li>",
"     <li>",
"      DZP (MY);",
"     </li>",
"     <li>",
"      Elcion CR (IN);",
"     </li>",
"     <li>",
"      Euphorin (JP);",
"     </li>",
"     <li>",
"      Gewacalm (AT);",
"     </li>",
"     <li>",
"      Horizon (JP);",
"     </li>",
"     <li>",
"      Ifa Fonal (MX);",
"     </li>",
"     <li>",
"      Kratium (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Lembrol (AR);",
"     </li>",
"     <li>",
"      Melode (KP);",
"     </li>",
"     <li>",
"      Nivalen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Nixtensyn (PH);",
"     </li>",
"     <li>",
"      Noan (BR, IT);",
"     </li>",
"     <li>",
"      Normabel (HR);",
"     </li>",
"     <li>",
"      Ortopsique (MX);",
"     </li>",
"     <li>",
"      Paceum (CH);",
"     </li>",
"     <li>",
"      Pacitran (PE);",
"     </li>",
"     <li>",
"      Pamizep (PH);",
"     </li>",
"     <li>",
"      Pax (ZA);",
"     </li>",
"     <li>",
"      Paxum (IN);",
"     </li>",
"     <li>",
"      Placidox 10 (IN);",
"     </li>",
"     <li>",
"      Placidox 2 (IN);",
"     </li>",
"     <li>",
"      Placidox 5 (IN);",
"     </li>",
"     <li>",
"      Plidan (AR);",
"     </li>",
"     <li>",
"      Propam (NZ);",
"     </li>",
"     <li>",
"      Psychopax (AT, CH);",
"     </li>",
"     <li>",
"      Radizepam (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Ranzepam (AU);",
"     </li>",
"     <li>",
"      Relanium (PL, RU);",
"     </li>",
"     <li>",
"      Renborin (JP);",
"     </li>",
"     <li>",
"      Seduxen (BB, BM, BS, BZ, EE, GY, HN, HU, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Serenzin (JP);",
"     </li>",
"     <li>",
"      Sipam (TH);",
"     </li>",
"     <li>",
"      Stesolid (AE, BH, CH, CY, DE, DK, EG, FI, HN, ID, IL, IQ, IR, JO, KW, LB, LY, NO, OM, QA, SA, SE, SY, TW, YE);",
"     </li>",
"     <li>",
"      Stesolid Rectal Tube (DE, HK);",
"     </li>",
"     <li>",
"      Sunzepam (MX);",
"     </li>",
"     <li>",
"      Tranquirit (IT);",
"     </li>",
"     <li>",
"      Valaxona (DK);",
"     </li>",
"     <li>",
"      Valdimex (ID);",
"     </li>",
"     <li>",
"      Valiquid (DE);",
"     </li>",
"     <li>",
"      Valisanbe (ID);",
"     </li>",
"     <li>",
"      Valium (AE, AR, AT, AU, BE, BF, BG, BH, BJ, BR, CH, CI, CY, DE, DK, EC, EE, EG, ES, ET, FR, GH, GM, GN, GR, HR, ID, IE, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, OM, PE, PH, PK, PL, PT, PY, QA, SA, SC, SD, SK, SL, SN, SY, TN, TR, TZ, UG, UY, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Valiuzam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Valpam (AE, AU, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Valzepam (PH);",
"     </li>",
"     <li>",
"      Vanconin (TW);",
"     </li>",
"     <li>",
"      Vatran (IT);",
"     </li>",
"     <li>",
"      Zopam (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Almost immediate; Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: 20-30 minutes; Oral: Variable (dose and frequency dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 85% to 100%, more reliable than I.M.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Young healthy males: 0.8-1.0 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Parent drug: Adults: 20-50 hours; increased half-life in neonates, elderly, and those with severe hepatic disorders; Active major metabolite (desmethyldiazepam): 50-100 hours; may be prolonged in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 15 minutes to 2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abernathy DR and Greenblatt DJ, &ldquo;Drug Disposition in Obese Humans. An Update,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1986, 11(3):199-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/3524955/pubmed\" id=\"3524955\" target=\"_blank\">",
"        3524955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allikmets E, et al, &ldquo;Long-Term Use of Benzodiazepines: Abrupt Withdrawal Versus Withdrawal Under Nifedipine Cover,&rdquo;",
"      <i>",
"       Pharmacol Toxicol",
"      </i>",
"      , 1995, 76(Suppl 3):Abstr 8.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bleck TB, Seizures, Stroke, and Other Neurologic Emergencies. In: Zimmerman JL, Roberts PR, eds.",
"      <i>",
"       Multidisciplinary Critical Care Review",
"      </i>",
"      , Des Plains, IL: Society of Critical Care Medicine; 2003, 325-34.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delgado MR, Hirtz D, Aisen M, et al, &ldquo;Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 74(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/20101040/pubmed\" id=\"20101040\" target=\"_blank\">",
"        20101040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engle HA, &ldquo;The Effect of Diazepam (Valium) in Children With Cerebral Palsy: A Double-Blind Study,&rdquo;",
"      <i>",
"       Dev Med Child Neurol",
"      </i>",
"      , 1966, 8(6):661-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/5339679/pubmed\" id=\"5339679\" target=\"_blank\">",
"        5339679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&auml;lvi&auml;inen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2007, 48(Suppl 8):99-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/18330014/pubmed\" id=\"18330014\" target=\"_blank\">",
"        18330014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(4):657-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/7699551/pubmed\" id=\"7699551\" target=\"_blank\">",
"        7699551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathew A, Mathew MC, Thomas M, et al, &ldquo;The Efficacy of Diazepam in Enhancing Motor Function in Children With Spastic Cerebral Palsy,&rdquo;",
"      <i>",
"       J Trop Pediatr",
"      </i>",
"      , 2005, 51(2):109-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/15840761/pubmed\" id=\"15840761\" target=\"_blank\">",
"        15840761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosman NP, Colton T, Labazzo J, et al, &ldquo;A Controlled Trial of Diazepam Administered During Febrile Illnesses to Prevent Recurrence of Febrile Seizures,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(2):79-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/8510706/pubmed\" id=\"8510706\" target=\"_blank\">",
"        8510706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Traeger SM and Haug MT 3d, &ldquo;Reduction of Diazepam Serum Half-Life and Reversal of Coma by Activated Charcoal in a Patient With Severe Liver Disease,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1986, 24(4):329-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/3746988/pubmed\" id=\"3746988\" target=\"_blank\">",
"        3746988",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(7):854-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/8340986/pubmed\" id=\"8340986\" target=\"_blank\">",
"        8340986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Treiman DM, Meyers PD, Walton NY, et al, &ldquo;A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 339(12):792-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/9738086/pubmed\" id=\"9738086\" target=\"_blank\">",
"        9738086",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Votey SR, Bosse GM, Bayer MJ, et al, &ldquo;Flumazenil: A New Benzodiazepine Antagonist,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1991, 20(2):181-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/1996802/pubmed\" id=\"1996802\" target=\"_blank\">",
"        1996802",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson KC, Reardon C, Theodore AC, et al, &ldquo;Propylene Glycol Toxicity: A Severe Iatrogenic Illness in ICU Patients Receiving IV Benzodiazepines: A Case Series and Prospective, Observational Pilot Study,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2005, 128(3):1674-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/16162774/pubmed\" id=\"16162774\" target=\"_blank\">",
"        16162774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/46/16105/abstract-text/2216645/pubmed\" id=\"2216645\" target=\"_blank\">",
"        2216645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9345 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16105=[""].join("\n");
var outline_f15_46_16105=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159080\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159035\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159055\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159036\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159037\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159038\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158984\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159082\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159006\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159088\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159005\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159077\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159090\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159078\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159009\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158988\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159074\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158993\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159026\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158996\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159013\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159041\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159014\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159012\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158998\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159002\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159015\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158987\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159008\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9345\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9345|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/58/25509?source=related_link\">",
"      Diazepam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=related_link\">",
"      Diazepam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16106="Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome";
var content_f15_46_16106=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Joseph P Carrozza, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Roger J Laham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/46/16106/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/46/16106/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptoms suggestive of an acute myocardial infarction (MI) and having electrocardiographic evidence of an acute MI manifested by ST elevations (&gt;1 mm in two contiguous leads after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    to rule out coronary vasospasm) that is considered to represent ischemia are candidates for reperfusion therapy with either primary percutaneous coronary intervention or fibrinolytic therapy. Patients with typical symptoms in the presence of a new or presumably new left bundle branch block or a true posterior MI are also considered eligible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=see_link\">",
"     \"Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coronary reperfusion with primary percutaneous coronary intervention (PPCI) or fibrinolytic therapy improves outcomes in patients with acute ST elevation myocardial infarction (STEMI) or an MI with a new or presumably new left bundle branch block or a true posterior MI. If performed in a timely fashion, PPCI is the reperfusion therapy of choice compared to fibrinolysis because it achieves a higher rate of TIMI 3 flow (more than 90 percent) (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ), does not carry the risk of intracranial hemorrhage, and is associated with improved outcomes. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Prognosis after primary PCI'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The time to onset of reperfusion therapy is a critical determinant of outcome with both PPCI and fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239839#H69239839\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Initiation of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the impact of the following factors on outcomes in patients who undergo PPCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time between symptom onset and PCI, also referred to as treatment delay (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Time from symptom onset on outcomes'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H152207030\">",
"       'Definitions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The time from hospital arrival to PCI (door-to-balloon time, or door-to-balloon delay) (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Time from hospital arrival (door-to-balloon time) on outcomes'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H152207030\">",
"       'Definitions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The time from first contact with the healthcare system (See",
"      <a class=\"local\" href=\"#H233520420\">",
"       'Time from contact with the healthcare system (System Delay)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Early versus late presentation (See",
"      <a class=\"local\" href=\"#H269831116\">",
"       'Early versus late presentation'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The risk category of the patient (See",
"      <a class=\"local\" href=\"#H269831123\">",
"       'Patient risk category'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Physician and hospital factors (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Importance of local expertise'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Importance of TIMI 3 flow (patent artery) (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis after primary PCI'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Periprocedural management issues and the outcomes after PPCI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The clinical trials demonstrating the benefit of PPCI compared to fibrinolytic therapy, selection of a reperfusion strategy, the possible role of PCI after fibrinolysis, and the role of PCI in non-ST elevation acute coronary syndromes are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152207030\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The total time between the onset of symptoms and primary percutaneous coronary intervention (PPCI), termed the treatment delay, has the following components [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient delay &mdash; This is the time between onset of symptoms and the call to the emergency medical system (EMS).",
"     </li>",
"     <li>",
"      Prehospital system delay &mdash; For patients taken to a percutaneous coronary intervention center (PCI center), this is the time between the EMS call and the arrival at the PCI center and is equivalent to the time of EMS evaluation, prehospital ECG obtainment (if any), and transportation to the hospital. For patients transferred from a local hospital to a PCI center, this is sum of the time between the EMS call and arrival at the local hospital, the time at the local hospital, and the time between hospitals (second transfer time).",
"     </li>",
"     <li>",
"      Door-to-balloon delay &mdash; This is the time between arrival at the PCI center and PPCI. Time of PPCI refers to the time of coronary intervention with a balloon, stent, or other intervention, not to be confused with the time of arrival in the catheterization laboratory or the time of vascular access.",
"     </li>",
"     <li>",
"      System delay &mdash; This is the sum of the prehospital system and door-to-balloon delays.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this schema, patient delay is not easily corrected by the healthcare system, while strategies to shorten other delays are potentially modifiable. Such an effort will be useful if longer time intervals are associated with worse outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TIME FROM SYMPTOM ONSET ON OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to fibrinolytic therapy, the benefit (myocardial salvage and functional improvement) is greatest when fibrinolytics are given within the first two to three hours after the onset of symptoms, particularly within the first 70 minutes (",
"    <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, many patients with STEMI present late after the development of symptoms. In different registries of patients, the time from symptom onset to hospital presentation was &ge;4 hours in 50 percent (a value that changed little from 1987 to 2000) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/5\">",
"     5",
"    </a>",
"    ], more than six hours in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/6\">",
"     6",
"    </a>",
"    ], and more than 12 hours in 9 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Data from a more recent observational study, found a lower percentage of late presenters (32 percent) in patients undergoing PPCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/1\">",
"     1",
"    </a>",
"    ]. Delay is greatest in women, older adults, low socioeconomic and ethnic minority groups, and in those with symptoms that occur between 6 PM and 6 AM [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/5,6,9\">",
"     5,6,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial studies primarily evaluated outcomes with percutaneous transluminal coronary angioplasty (PTCA) without stenting, which is no longer the standard procedure. The data were conflicting as to whether there is [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/10-13\">",
"     10-13",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] a significant relationship between mortality and the time from symptom onset to reperfusion similar to that seen with fibrinolytic therapy with PTCA.",
"   </p>",
"   <p>",
"    Although outcomes are improved with PTCA plus stenting compared to PTCA alone, published data are limited on the prognostic importance of the time from symptom onset to reperfusion with stenting and the evidence is inconclusive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two small cardiovascular magnetic resonance (CMR) studies, which evaluated the relationship between the time from symptom onset to PPCI with stenting and myocardial infarction size, came to differing conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The best available data come from a study of 6209 patients in a Denmark registry who underwent PCI with stenting between 2002 and 2008 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/2\">",
"       2",
"      </a>",
"      ]. In the multivariable analysis, there was no significant relationship between onset of symptoms and PPCI (treatment delay) and long-term mortality. However, components of the treatment delay were significantly related to outcome. The impact of the components of treatment delay on mortality is discussed below. (See",
"      <a class=\"local\" href=\"#H233520420\">",
"       'Time from contact with the healthcare system (System Delay)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible explanations for the absence of clear evidence to support a relationship between better outcomes and shorter time between symptom onset and PCI include the fact that patients are poor informants about the onset of symptoms, the period of intermittent thrombotic obstruction of the artery associated with stuttering of symptoms before total occlusion (lack of clarity as to what percent of the time is unstable angina), the improved effectiveness of PPCI versus fibrinolytics in late presenters (see below), the use of more aggressive antithrombotic therapies in the era of stenting, and patients with later presentation being less ill (survivor cohort effect) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The interaction between time from symptom onset to PPCI and the interval between hospital arrival and PPCI (door-to-balloon time) is discussed below. (See",
"    <a class=\"local\" href=\"#H269831116\">",
"     'Early versus late presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269830214\">",
"    <span class=\"h2\">",
"     Late PCI to open an occluded artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to fibrinolysis, revascularization after 12 hours with PCI could be beneficial in the 9 to 31 percent of patients with STEMI who present more than 12 hours after the onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H69239847#H69239847\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been estimated that, in the absence of reperfusion therapy, the infarct-related artery is still occluded at 12 to 24 hours in 65 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/18\">",
"     18",
"    </a>",
"    ]. The establishment of TIMI 3 flow, as discussed below, may be of benefit in these patients. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Prognosis after primary PCI'",
"    </a>",
"    below.) The randomized trials that have evaluated routine late PCI have included patients at different time periods after symptom onset, ranging from more than 12 hours to up to 28 days. Some have demonstrated an improvement in left ventricular function with intervention, but none have demonstrated a significant benefit on hard clinical outcomes. The role of late PCI to open an occluded artery is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link&amp;anchor=H26#H26\">",
"     \"Coronary artery patency and outcome after myocardial infarction\", section on 'Late PCI to open an occluded artery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines concluded that it is reasonable to perform PPCI for patients with onset of symptoms within the prior 12 to 24 hours who have one or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe heart failure",
"     </li>",
"     <li>",
"      Hemodynamic or electrical instability",
"     </li>",
"     <li>",
"      Persistent ischemic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, the task force did",
"    <strong>",
"     not",
"    </strong>",
"    recommend PPCI in stable, asymptomatic patients presenting more than 12 hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=see_link&amp;anchor=H26#H26\">",
"     \"Coronary artery patency and outcome after myocardial infarction\", section on 'Late PCI to open an occluded artery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009 focused update of the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    did not change the approach described above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TIME FROM HOSPITAL ARRIVAL (DOOR-TO-BALLOON TIME) ON OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the uncertain relationship between mortality and the time from symptom onset to balloon inflation, the time from hospital arrival to balloon inflation (the door-to-balloon time) has been relatively well studied and is predictive of in-hospital mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/1,10,14,21-25\">",
"     1,10,14,21-25",
"    </a>",
"    ]. Evidence for a detrimental effect of longer door-to-balloon times (DTBTs) on outcomes comes from both observational studies and randomized trials: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 29,222 STEMI patients in the NRMI-3 and 4 registries (1999 to 2002) who were treated with PCI within six hours of presentation, longer DTBTs were significantly associated with increased in-hospital mortality (3.0, 4.2, 5.7, and 7.4 percent for DTBT of &le;90 minutes, 91 to 120 minutes, 121 to 150 minutes, and &gt;150 minutes, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients with DTBTs &gt;90 minutes had a significant increase in mortality compared to those with DTBTs &le;90 minutes (odds ratio 1.42, after adjusting for patient characteristics).",
"     </li>",
"     <li>",
"      In a systematic evaluation of 1440 STEMI patients who received PPCI during 2006 to 2007 in Quebec, Canada, DTBTs exceeded 90 minutes in 68 percent; death or readmission for MI or heart failure at one year occurred in 13.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/1\">",
"       1",
"      </a>",
"      ]. Mortality at 30 days and one year occurred significantly less frequently in those with DTBTs &le;90 minutes compared to those with longer DTBTs (3.4 versus 6.1 percent; odds ratio [OR] 1.87, 95% CI 1.02-3.41 and 5.5 versus 9.1 percent; OR 1.71, 95% CI 1.06-2.76, respectively).",
"     </li>",
"     <li>",
"      In an analysis of 4548 patients enrolled in the CADILLAC and HORIZONS-AMI trials, short door-to-balloon times (&le;90 minutes) were associated with a significantly lower mortality rate at one year compared to longer times (3.1 versus 4.3 percent; hazard ratio 0.72, 95% CI 0.52-0.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H14#H14\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Primary PCI'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these observations, one- and six-month mortality in the Stent PAMI trial were similar in patients with a DTBT less than or more than two hours (3.4 versus 3.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/15\">",
"     15",
"    </a>",
"    ]. The reasons for the discrepant findings are not clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18640015\">",
"    <span class=\"h2\">",
"     Outcomes in patient subgroups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether the improvement in survival with short DTBTs is delivered equally to all patients has been studied, and two subgroups of patients appear to benefit the most: those who present early after symptom onset and those at high risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269831116\">",
"    <span class=\"h3\">",
"     Early versus late presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to early versus late presentation, it appears that short DTBT is associated with improved outcome in early presenters more than in late presenters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 2322 patients who underwent PPCI comparing short versus long DTBT (&lt;2 versus &gt;2 hours) with either balloon angioplasty or stenting, there was a significant decrease in seven-year mortality in patients presenting &le;3 hours from symptom onset (15.0 versus 24.7 percent), but not in patients presenting after three hours (18.5 versus 21.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of 4548 patients who underwent PPCI with stenting in the CADILLAC and HORIZONS-AMI trials, short (&le;90 minutes) compared to long DTBTs were associated with a significantly lower one-year mortality rate in patients with early presentation (&le;90 minutes versus &ge;90 minutes), but not those with later presentation (1.9 versus 3.8 percent, hazard ratio 0.86, 95% CI 0.26-0.93 and 4.0 versus 4.6 percent, hazard ratio 0.86, 95% CI 0.58-1.28 respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link&amp;anchor=H3#H3\">",
"       \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Classification of anticoagulant agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H269831123\">",
"    <span class=\"h3\">",
"     Patient risk category",
"    </span>",
"    &nbsp;&mdash;&nbsp;With regard to risk category, it appears that high-risk patients benefit more from short DTBT:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the study of 2322 patients discussed above, there was a significant decrease in seven-year mortality with shorter DTBTs (&lt;2 versus &ge;2 hours) in high-risk (21.5 versus 32.5 percent) but not low-risk patients (9.2 versus 10.8 percent). High risk was defined as one or more of Killip class 3 or 4 heart failure (",
"      <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"       table 2",
"      </a>",
"      ), age &gt;70 years, or anterior MI.",
"     </li>",
"     <li>",
"      In the analysis of 4548 patients discussed above, short compared to long DTBTs showed a trend toward lower one-year mortality in both high-risk and low-risk groups (5.7 versus 7.4 and 1.1 versus 1.6 percent respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/25\">",
"       25",
"      </a>",
"      ]. In patients presenting early (&le;90 min), the hazard ratios for mortality rate in patients with short versus long DTBTs were identical for high- versus low-risk patients, but the absolute mortality rate differences were greater in high-risk patients (3.3 versus 0.7 percent). In patients presenting late (&gt;90 minutes), mortality was similar with short and long DTBTs in both high- and low-risk patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The findings above suggest that short door-to-balloon times are critically important in patients who present early, especially in high-risk patients. The impact of PCI-related delay on decision making in the individual patient is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H12#H12\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'PCI-related delay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233520420\">",
"    <span class=\"h1\">",
"     TIME FROM CONTACT WITH THE HEALTHCARE SYSTEM (SYSTEM DELAY)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The door-to-balloon delay represents only a portion of the total time that the STEMI patient is managed by the healthcare system. This longer time interval, referred to as system delay, is the sum of the prehospital system and door-to-balloon delays. For patients first brought to a hospital without PCI capability, the system delay has multiple components. (See",
"    <a class=\"local\" href=\"#H152207030\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The associations between healthcare delays and mortality were evaluated in a study of 6209 patients with STEMI from 2002 to 2006 who were included in large, public medical databases in Western Denmark [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/2\">",
"     2",
"    </a>",
"    ]. Approximately one-third of these patients were field-triaged to a PCI center and two-thirds were admitted to a local hospital and then transferred to a PCI center. In this cohort the median follow-up time was 3.4 years and the cumulative one-year mortality was 9.3 percent. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the univariable analysis of the components of delay (system, prehospital system, door-to-balloon, treatment, and patient), system delay had the strongest association with mortality (hazard ratios [HR] 1.22, 1.19, 1.13, 1.054, and 1.042, respectively). All hazard ratios were significant.",
"     </li>",
"     <li>",
"      For system delays of 0 to 60 minutes, 61 to 120 minutes, 121 to 180 minutes, and 181 to 360 minutes, the long-term cumulative mortality was 15.4, 23.3, 28.1, and 30.8 percent, respectively.",
"     </li>",
"     <li>",
"      In the multivariable analysis, treatment delay and patient delay were not associated with mortality, but system delay was independently associated with mortality (HR 1.10, 95% CI 1.01-1.16 per one-hour delay). The main components of system delay, prehospital system delay and door-to-balloon delay, were similarly associated with mortality (HR 1.10, 95% CI 1.02-1.18 and 1.14, 95% CI 1.05-1.24, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While this study demonstrates the negative impact of increasing system delay on mortality, it does not allow any firm conclusion regarding the time at which an alternative strategy using a fibrinolytic agent would be preferable. (See",
"    <a class=\"local\" href=\"#H233521064\">",
"     'Transfer from a non-PCI center'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    We believe that the earlier a patient presents (and thus a higher baseline risk), the less door-to-balloon delay that is acceptable. Thus, fibrinolytic therapy is an important option for patients who present within the first three hours and who are at a low risk of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233520601\">",
"    <span class=\"h2\">",
"     Direct transfer from the field",
"    </span>",
"    &nbsp;&mdash;&nbsp;As pointed out by the authors of the Western Denmark study discussed above, one implication of worse outcomes with longer door-to-balloon times is that mortality may be improved with direct transfer to a PCI hospital compared with evaluation and treatment at a closer hospital without PCI capability. The feasibility and impact of this strategy on door-to-balloon delay was evaluated in a nonrandomized comparison of 344 patients with chest pain of less than 12 hours duration and ST-segment elevation characteristic of acute MI in 2005 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/27\">",
"     27",
"    </a>",
"    ]. In this study, 135 patients were referred directly from the field by paramedics trained in ECG interpretation and 209 patients were referred directly from regional emergency departments. The median door-to-balloon time, defined as the time between arrival at the first hospital to first balloon inflation, was significantly shorter in patients referred from the field (69 versus 123 minutes) and the percent of patients with door-to-balloon times of less than 90 minutes was significantly higher (80 versus 12).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233521064\">",
"    <span class=\"h2\">",
"     Transfer from a non-PCI center",
"    </span>",
"    &nbsp;&mdash;&nbsp;The worse outcomes seen with longer door&ndash;to-balloon times are of particular concern for patients with acute MI who are initially evaluated at hospitals without on-site PCI capability. The time spent at the first hospital, the subsequent transfer time, and the time spent at the receiving hospital prior arrival in the catheterization laboratory are sources of longer door-to-balloon times. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    above.) The frequency, magnitude, and clinical impact of delays occurring at each of these time intervals were examined in a prospective study of 2034 patients referred to a PCI center (Minneapolis, Minnesota, USA) for primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/28\">",
"     28",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delays occurred most frequently in the emergency department at the referral hospital, with less delay seen at the PCI center or in transport (64, 16, and 13 percent, respectively).",
"     </li>",
"     <li>",
"      For the referral hospital, the most frequent reasons for delay were awaiting transport and emergency department delays (26 and 14 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic dilemmas, including nondiagnostic initial ECGs, led to the greatest delay, but these had limited or no impact on mortality. The door-in to door-out (DIDO) time is defined as the duration of time from arrival to discharge at the first (STEMI referral) hospital. The DIDO time is probably modifiable, as opposed to the non-modifiable delay caused by an additional ambulance ride. As a result, the DIDO time has become a performance measure of the United States Centers for Medicare and Medicaid Services [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/29\">",
"     29",
"    </a>",
"    ]. The 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association Clinical Performance Measures for Acute Myocardial infarction recommend a DIDO time of less than 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between DIDO time and outcomes was evaluated in a study of nearly 15,000 patients who initially presented to a STEMI referral hospital and were subsequently transferred to a PCI facility; the patients were enrolled in the Acute Coronary Treatment and Intervention Outcomes Network (ACTION) Registry-Get With the Guidelines (GWTG) between 2007 and 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/31\">",
"     31",
"    </a>",
"    ]. Exclusion criteria were fibrinolytic therapy, the need for rescue or facilitated PCI, or a planned pharmacoinvasive approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=see_link&amp;anchor=H1293488#H1293488\">",
"     \"Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction\", section on 'Pharmacoinvasive strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median DIDO time was 68 minutes, with only 11 percent of patients having a goal DIDO time of less than 30 minutes.",
"     </li>",
"     <li>",
"      Predictors of longer DIDO times included older age, female sex, off-hours presentation (any time other than 8 AM to 5 PM Monday through Friday), and non-emergency medical services presentation to the first hospital.",
"     </li>",
"     <li>",
"      Patients with DIDO times less than 30 minutes had significantly shorter door-to-balloon times (85 versus 127 minutes) and a lower in-hospital mortality rate (2.7 versus 5.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for reperfusion in patients in whom a significant delay in transfer is anticipated are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link&amp;anchor=H12#H12\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\", section on 'PCI-related delay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H233521475\">",
"    <span class=\"h3\">",
"     False positive cath lab activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strategies that may decrease door-to-balloon time in patients transferred for primary PCI allow cardiac catheterization laboratory activation by the practitioners at the referring hospital or in the field. A weakness of this strategy could be referral of patients who are not candidates for PCI by practitioners who are potentially less skilled in ECG interpretation.",
"   </p>",
"   <p>",
"    The frequency of false-positive referrals and the associated diagnoses were evaluated in a prospective registry of 1335 patients referred from 30 hospitals in Minnesota and Wisconsin between 2003 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/32\">",
"     32",
"    </a>",
"    ]. False positive was defined as no culprit coronary artery (present in 14 percent), negative biomarkers (11.2 percent), or both (9.2 percent). In those patients, with negative biomarkers, the most common discharge diagnoses were early repolarization, nondiagnostic ECG, previous MI, left bundle branch block, and pericarditis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106809928\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2013 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association guideline for the management of STEMI recommends the timely performance of primary PCI and sets the following time goals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who initially arrive at or are transported to a non-PCI capable hospital, the first medical contact to device time should be 120 minutes or less.",
"     </li>",
"     <li>",
"      For patients who initially arrive at or are transported to a PCI capable hospital, the first medical contact to device time should be 90 minutes or less.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2012 European Society of Cardiology guideline on STEMI recommended shorter time intervals of 90 and 60 minutes, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152206999\">",
"    <span class=\"h1\">",
"     OTHER FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hospital performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time from hospital arrival to primary percutaneous coronary intervention (PPCI) in the United States is decreasing slowly. In large surveys, the median DTBT fell from 120 minutes from 1994 to 1995 to 108 minutes from 1999 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]; however, between 1999 and 2002, only 35 percent of patients met the recommended goal of less than 90 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/37\">",
"     37",
"    </a>",
"    ]. The median DTBT time was higher (180 minutes) among patients transferred for PPCI, as only 4.2 percent met the recommended goal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The (United States) National Registry of Myocardial Infarction (NRMI) evaluated outcomes in over 900,000 STEMI patients who were eligible for reperfusion upon arrival to the hospital between 1990 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/39\">",
"     39",
"    </a>",
"    ]. DTBT among nontransferred patients declined significantly from 111 minutes in 1994 to 79 minutes in 2006.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Performance improvement strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of successful hospitals have identified a number of organizational strategies that contributed to minimizing treatment delay [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. In a multivariate analysis of 365 hospitals, six strategies that reduced DTBT were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergency medicine physician ability to activate the catheterization laboratory (mean reduction in DTBT, 8.2 minutes)",
"     </li>",
"     <li>",
"      Single call to a central page operator who activates the catheterization laboratory (13.8 minutes)",
"     </li>",
"     <li>",
"      Expectation that staff will arrive in the catheterization laboratory within 20 minutes after being paged compared to more than 30 minutes (19.3 minutes)",
"     </li>",
"     <li>",
"      Having an attending cardiologist always on site (14.6 minutes)",
"     </li>",
"     <li>",
"      Having staff in the emergency department and the catheterization laboratory use real-time feedback (8.6 minutes)",
"     </li>",
"     <li>",
"      Emergency department activation of the catheterization laboratory while the patient is en route (15.4 minutes)",
"     </li>",
"     <li>",
"      Regular audits of performance times",
"     </li>",
"     <li>",
"      Standard and simple algorithms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More robust improvement in DTBT was demonstrated in a subsequent prospective, single-center study of a strategy designed to improve DTBT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/43\">",
"     43",
"    </a>",
"    ]. The hospital intervention included mandated emergency department physician activation of the catheterization laboratory and immediate transfer of the patient to an immediately available catheterization laboratory by an in-house nursing transfer team. DTBT were compared between 60 STEMI patients cared for between October 2004 and August 2005 (preintervention) and 86 STEMI patients cared for between September 2005 and June 2006 (postintervention).",
"   </p>",
"   <p>",
"    The following statistically-significant improvements were seen in the postintervention period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median DTBT decreased overall (114 versus 76 minutes)",
"     </li>",
"     <li>",
"      DTBT during regular hours (84 versus 65 minutes)",
"     </li>",
"     <li>",
"      DTBT during off hours (124 versus 78 minutes)",
"     </li>",
"     <li>",
"      Treatment within 90 minutes increased from 28 to 71 percent",
"     </li>",
"     <li>",
"      Mean infarct size decreased (peak creatinine kinase 2623 versus 1517",
"      <span class=\"nowrap\">",
"       IU/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant improvement in DTBT as a result of the ability to transmit the prehospital electrocardiogram has been demonstrated in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In a NRMI-4 report, the catheterization laboratory was activated as a consequence of the prehospital electrocardiogram in about 6 percent of over 56,000 patients with STEMI seen between 2000 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/46\">",
"     46",
"    </a>",
"    ]. This interaction was associated with significant reductions in mean DTBT with PPCI (94 versus 110 minutes) and mean door-to-drug time with fibrinolytic therapy (24 versus 35 minutes).",
"   </p>",
"   <p>",
"    The strong evidence supporting better outcomes of PCI with multiple performance improvement strategies has led to the inclusion of shorter DTBT as a quality indicator in practice guidelines and the development of pay for performance reimbursement by insurers to hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF LOCAL EXPERTISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is whether the results from controlled clinical trials at major centers can be applied to community practice. The ability to perform emergent PCI on a 24-hour basis requires a complex organization and the firm commitment of the catheterization laboratory staff. These logistic issues make primary percutaneous coronary intervention (PPCI) less available, especially at smaller, low-volume hospitals (",
"    <a class=\"graphic graphic_table graphicRef80948 \" href=\"UTD.htm?34/42/35500\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73459 \" href=\"UTD.htm?43/31/44540\">",
"     table 4",
"    </a>",
"    ). It is therefore not surprising that results following PPCI vary among different centers and different physicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hospital and operator volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the variation in results among institutions can be attributed to differences in the annual volume of PPCI at an individual hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/14,47-50\">",
"     14,47-50",
"    </a>",
"    ]. This can be illustrated in a NRMI review of PPCI and fibrinolysis in over 62,000 patients from 446 acute-care hospitals in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/47\">",
"     47",
"    </a>",
"    ]. Primary PCI was associated with reduced mortality compared to fibrinolysis in high-volume (&ge;49 procedures, 3.4 versus 5.4 percent) and intermediate-volume hospitals (17 to 48 procedures, 4.5 versus 5.9 percent); the degree of benefit was similar to that seen in the large randomized trials. In contrast, there was no mortality benefit with PPCI in low-volume hospitals (&le;16 procedures, 6.2 versus 5.9 percent), but the total stroke rate was significantly reduced (0.4 versus 1.1 percent).",
"   </p>",
"   <p>",
"    Two additional findings were noted in a second NRMI analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/48\">",
"     48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mortality rate after PPCI was significantly lower in high-volume compared to lower-volume hospitals (relative risk 0.72). The absolute difference of approximately 2 per 100 patients treated was independent of the number of MIs seen at the hospitals.",
"     </li>",
"     <li>",
"      There was no significant relationship between the volume of fibrinolytic interventions and in-hospital mortality (7.0 versus 6.9 at the highest- versus lowest-volume hospitals).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions guideline for PCI recommended that primary PCI be performed by experienced operators (&gt;75 elective PCI procedures per year, of which at least 11 are ideally for STEMI) at high-volume centers (&gt;400 PCI procedures per year, of which at least 36 are ideally for STEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The benefit of PPCI was considered less well-established for less-experienced operators in patients who are eligible for fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PCI without on-site cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best treat complications of PCI, on-site cardiac surgery may be required by state regulations and community standards. There is increasing evidence, however, that, when performed by experienced operators, PPCI without cardiac surgery produces better outcomes than fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. This is particularly true with the use of stents, which has largely eliminated the problem of acute vessel closure.",
"   </p>",
"   <p>",
"    The outcome with these two strategies in hospitals without on-site cardiac surgery was addressed by the C-PORT trial in which 451 fibrinolysis-eligible patients with an acute MI seen within 12 hours of symptoms were randomly assigned to PCI or fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/53\">",
"     53",
"    </a>",
"    ]. Patients undergoing PPCI had a significantly lower incidence of the composite endpoint (death, recurrent MI, and stroke) at six months (12.4 versus 20 percent for fibrinolysis); the difference in outcome was primarily due to a lower rate of recurrent MI (5.3 versus 10.6 percent).",
"   </p>",
"   <p>",
"    The issue of whether primary PCI can be safely performed at hospitals without on-site cardiac surgery was addressed in a 2011 meta-analysis of 11 studies that included over 124,000 STEMI patients treated with primary PCI that compared outcomes between hospitals without and with on-site cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/56\">",
"     56",
"    </a>",
"    ]. Comparing hospitals without to those with on-site surgery, there was no increase in the observed risk of in-hospital mortality (4.3 versus 7.2 percent, respectively; odds ratio [OR] 0.96, 95% CI 0.88-1.05 or emergency bypass 0.22 versus 1.03 percent; OR 0.53, 95% CI 0.35-0.79).",
"   </p>",
"   <p>",
"    The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Angiography and Interventions guideline for PCI made a weak recommendation for PPCI at institutions without on-site cardiac surgery that met certain institutional and operator criteria (",
"    <a class=\"graphic graphic_table graphicRef68713 \" href=\"UTD.htm?33/37/34396\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS AFTER PRIMARY PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis after primary PCI (PPCI) is influenced by angiographic, electrocardiographic, and clinical factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443272219\">",
"    <span class=\"h2\">",
"     TIMI flow grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it takes longer to implement PPCI than to administer fibrinolytic therapy, PPCI is associated with a much higher rate of attaining angiographically normal (TIMI 3) flow (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ): 93 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/57,58\">",
"     57,58",
"    </a>",
"    ] compared to 50 to 60 percent with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. This is an important limitation of fibrinolytic therapy since benefit is only seen in those who attain TIMI 3 flow (",
"    <a class=\"graphic graphic_figure graphicRef75629 graphicRef70952 \" href=\"UTD.htm?24/1/24606\">",
"     figure 2A-B",
"    </a>",
"    ). Suboptimal reperfusion, as estimated in part from the post-PCI TIMI flow grade (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ), is an important determinant of prognosis after PPCI. Mortality is worse after PPCI in the small number of patients who do not attain TIMI 3 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/21,57,62\">",
"     21,57,62",
"    </a>",
"    ]. In a review from the PAMI trials, 232 of 3362 patients (6.9 percent) did not attain TIMI 3 flow; the adjusted one-year mortality in those with and without TIMI 3 flow was 3 versus 14 percent; most of this difference occurred within the first 30 days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/57\">",
"     57",
"    </a>",
"    ]. Lack of attainment of TIMI 3 flow was a significant independent predictor of mortality (adjusted hazard ratio 3.8, 95% CI 2.5-5.7). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443272427\">",
"    <span class=\"h2\">",
"     Electrocardiographic markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic markers can successfully predict outcome in the broad range of patients with STEMI. In the first prospective evaluation of electrocardiographic markers in patients undergoing PPCI, the prognostic utility of six different methods for evaluating the extent of ST-segment elevation resolution after PCI was assessed in 4866 patients enrolled in the APEX-AMI trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/63\">",
"     63",
"    </a>",
"    ]. All six methods were successful in predicting outcomes death or the composite of death, cardiogenic shock or heart failure at 90 days. One of these, the measurement of the residual, absolute ST elevation in the single, most affected (worst) lead 30 minutes after PCI, performed as well as the more complex methods. Data from additional therapeutic trials are needed before this marker can be considered a reasonable surrogate for clinical outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link&amp;anchor=H5#H5\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\", section on 'ECG for prognosis in STEMI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443272420\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors including Killip class (",
"    <a class=\"graphic graphic_table graphicRef65592 \" href=\"UTD.htm?3/59/4027\">",
"     table 2",
"    </a>",
"    ), age, and the number of diseased vessels are also important. These parameters have been incorporated into two risk models that have been prospectively validated: the Zwolle risk index, the TIMI risk score, and the CADILLAC risk score (",
"    <a class=\"graphic graphic_table graphicRef70537 \" href=\"UTD.htm?2/61/3036\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/46/16106/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk stratification for cardiac events after acute ST elevation myocardial infarction\", section on 'Primary PCI scores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general discussion of the prognosis after myocardial infarction is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41769?source=see_link\">",
"     \"Prognosis after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following conclusions can be reached from the clinical trials and observational studies discussed above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary percutaneous coronary intervention (PPCI) with stenting if performed in a timely manner is associated with better outcomes than fibrinolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"       \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"       \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The time from symptom onset to PCI has not been shown to be an important determinant of outcome. At the least, the benefit from PPCI is less dependent upon the time from symptom onset than is fibrinolysis (",
"      <a class=\"graphic graphic_figure graphicRef53374 \" href=\"UTD.htm?30/18/31021\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Time from symptom onset on outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The time from hospital arrival to PCI (door-to-balloon time) is an important determinant of benefit, with the best outcomes occurring when the time to PCI is 90 minutes or less. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Time from hospital arrival (door-to-balloon time) on outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing system delay is associated with worse outcomes. (See",
"      <a class=\"local\" href=\"#H233520420\">",
"       'Time from contact with the healthcare system (System Delay)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are transferred to a PCI center have better outcomes than those treated with fibrinolysis at the presenting hospital if PPCI is delivered according to guidelines standards. Most of the benefit in these trials is due to a lower rate of reinfarction after PCI, which is unrelated to the time required for transfer. (See",
"      <a class=\"local\" href=\"#H233521064\">",
"       'Transfer from a non-PCI center'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Destination protocols for EMS that bypass non-PPCI capable hospitals and thereby shorten system delays to PPCI have been associated with improved outcomes in STEMI. (See",
"      <a class=\"local\" href=\"#H152206999\">",
"       'Other factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitals should adapt strategies to reduce door-to-balloon times and thereby improve outcomes in STEMI patients treated with PPCI. (See",
"      <a class=\"local\" href=\"#H152206999\">",
"       'Other factors'",
"      </a>",
"      above.) All hospitals should meet American College of Cardiology",
"      <span class=\"nowrap\">",
"       Foundation/American",
"      </span>",
"      Heart Association criteria for institutional and operator volumes in hospitals with or without on-site cardiac surgery. The door-to-balloon time should be less than two hours. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Importance of local expertise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late PCI to open an occluded artery should be considered in patients with severe heart failure, hemodynamic or electrical instability, or persistent ischemic symptoms. (See",
"      <a class=\"local\" href=\"#H269830214\">",
"       'Late PCI to open an occluded artery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PPCI should not be performed in hospitals without on-site cardiac surgery unless they meet specific criteria, including having a proven plan for rapid transport to a cardiac surgery operating room in a nearby hospital and having appropriate hemodynamic support capability for transfer. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'PCI without on-site cardiac surgery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The discussion of the use of these observations to formulate a reperfusion strategy for the individual patient is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=see_link\">",
"     \"Selecting a reperfusion strategy for acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/1\">",
"      Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA 2010; 303:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/2\">",
"      Terkelsen CJ, S&oslash;rensen JT, Maeng M, et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010; 304:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/3\">",
"      Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/4\">",
"      Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet 1994; 343:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/5\">",
"      McGinn AP, Rosamond WD, Goff DC Jr, et al. Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987-2000. Am Heart J 2005; 150:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/6\">",
"      Gurwitz JH, McLaughlin TJ, Willison DJ, et al. Delayed hospital presentation in patients who have had acute myocardial infarction. Ann Intern Med 1997; 126:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/7\">",
"      Eagle KA, Goodman SG, Avezum A, et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002; 359:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/8\">",
"      Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA 2003; 290:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/9\">",
"      Goff DC Jr, Feldman HA, McGovern PG, et al. Prehospital delay in patients hospitalized with heart attack symptoms in the United States: the REACT trial. Rapid Early Action for Coronary Treatment (REACT) Study Group. Am Heart J 1999; 138:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/10\">",
"      Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 1998; 32:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/11\">",
"      De Luca G, Suryapranata H, Zijlstra F, et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/12\">",
"      De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 2004; 109:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/13\">",
"      Tarantini G, Cacciavillani L, Corbetti F, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. J Am Coll Cardiol 2005; 46:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/14\">",
"      Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000; 283:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/15\">",
"      Brodie BR, Stone GW, Morice MC, et al. Importance of time to reperfusion on outcomes with primary coronary angioplasty for acute myocardial infarction (results from the Stent Primary Angioplasty in Myocardial Infarction Trial). Am J Cardiol 2001; 88:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/16\">",
"      Francone M, Bucciarelli-Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: insight from cardiovascular magnetic resonance. J Am Coll Cardiol 2009; 54:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/17\">",
"      Aquaro GD, Pingitore A, Strata E, et al. Relation of pain-to-balloon time and myocardial infarct size in patients transferred for primary percutaneous coronary intervention. Am J Cardiol 2007; 100:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/18\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/19\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/20\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/21\">",
"      Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999; 100:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/22\">",
"      Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/23\">",
"      McNamara RL, Wang Y, Herrin J, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006; 47:2180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/24\">",
"      Juliard JM, Feldman LJ, Golmard JL, et al. Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) time. Am J Cardiol 2003; 91:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/25\">",
"      Brodie BR, Gersh BJ, Stuckey T, et al. When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol 2010; 56:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/26\">",
"      Brodie BR, Hansen C, Stuckey TD, et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. J Am Coll Cardiol 2006; 47:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/27\">",
"      Le May MR, So DY, Dionne R, et al. A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med 2008; 358:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/28\">",
"      Miedema MD, Newell MC, Duval S, et al. Causes of delay and associated mortality in patients transferred with ST-segment-elevation myocardial infarction. Circulation 2011; 124:1636.",
"     </a>",
"    </li>",
"    <li>",
"     Measure summary: acute myocardial infarction: median time to transfer to another facility for acute coronary intervention. file://www.qualitymeasures.ahrq.gov/content.aspx?id=13121 (Accessed on July 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/30\">",
"      Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for ST-Elevation and Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American Academy of Family Physicians and American College of Emergency Physicians Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. J Am Coll Cardiol 2008; 52:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/31\">",
"      Wang TY, Nallamothu BK, Krumholz HM, et al. Association of door-in to door-out time with reperfusion delays and outcomes among patients transferred for primary percutaneous coronary intervention. JAMA 2011; 305:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/32\">",
"      Larson DM, Menssen KM, Sharkey SW, et al. \"False-positive\" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA 2007; 298:2754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/33\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/34\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/35\">",
"      Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/36\">",
"      Burwen DR, Galusha DH, Lewis JM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-1995 and 1998-1999: the medicare health care quality improvement program. Arch Intern Med 2003; 163:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/37\">",
"      McNamara RL, Herrin J, Bradley EH, et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. J Am Coll Cardiol 2006; 47:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/38\">",
"      Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/39\">",
"      Gibson CM, Pride YB, Frederick PD, et al. Trends in reperfusion strategies, door-to-needle and door-to-balloon times, and in-hospital mortality among patients with ST-segment elevation myocardial infarction enrolled in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/40\">",
"      Bradley EH, Roumanis SA, Radford MJ, et al. Achieving door-to-balloon times that meet quality guidelines: how do successful hospitals do it? J Am Coll Cardiol 2005; 46:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/41\">",
"      Bradley EH, Curry LA, Webster TR, et al. Achieving rapid door-to-balloon times: how top hospitals improve complex clinical systems. Circulation 2006; 113:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/42\">",
"      Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door-to-balloon time in acute myocardial infarction. N Engl J Med 2006; 355:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/43\">",
"      Khot UN, Johnson ML, Ramsey C, et al. Emergency department physician activation of the catheterization laboratory and immediate transfer to an immediately available catheterization laboratory reduce door-to-balloon time in ST-elevation myocardial infarction. Circulation 2007; 116:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/44\">",
"      Dhruva VN, Abdelhadi SI, Anis A, et al. ST-Segment Analysis Using Wireless Technology in Acute Myocardial Infarction (STAT-MI) trial. J Am Coll Cardiol 2007; 50:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/45\">",
"      Moscucci M, Eagle KA. Reducing the door-to-balloon time for myocardial infarction with ST-segment elevation. N Engl J Med 2006; 355:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/46\">",
"      Curtis JP, Portnay EL, Wang Y, et al. The pre-hospital electrocardiogram and time to reperfusion in patients with acute myocardial infarction, 2000-2002: findings from the National Registry of Myocardial Infarction-4. J Am Coll Cardiol 2006; 47:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/47\">",
"      Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000; 284:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/48\">",
"      Canto JG, Every NR, Magid DJ, et al. The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators. N Engl J Med 2000; 342:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/49\">",
"      Vakili BA, Kaplan R, Brown DL. Volume-outcome relation for physicians and hospitals performing angioplasty for acute myocardial infarction in New York state. Circulation 2001; 104:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/50\">",
"      Spaulding C, Morice MC, Lancelin B, et al. Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry. Eur Heart J 2006; 27:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/51\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/52\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/53\">",
"      Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/54\">",
"      Wharton TP Jr, McNamara NS, Fedele FA, et al. Primary angioplasty for the treatment of acute myocardial infarction: experience at two community hospitals without cardiac surgery. J Am Coll Cardiol 1999; 33:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/55\">",
"      Wennberg DE, Lucas FL, Siewers AE, et al. Outcomes of percutaneous coronary interventions performed at centers without and with onsite coronary artery bypass graft surgery. JAMA 2004; 292:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/56\">",
"      Singh M, Holmes DR Jr, Dehmer GJ, et al. Percutaneous coronary intervention at centers with and without on-site surgery: a meta-analysis. JAMA 2011; 306:2487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/57\">",
"      Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/58\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/59\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/60\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/61\">",
"      Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/62\">",
"      Ernst NM, Timmer JR, Zijlstra F, et al. Impact of failed mechanical reperfusion in patients with acute myocardial infarction treated with primary angioplasty. Am J Cardiol 2005; 96:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/63\">",
"      Buller CE, Fu Y, Mahaffey KW, et al. ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation 2008; 118:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/64\">",
"      De Luca G, Suryapranata H, van 't Hof AW, et al. Prognostic assessment of patients with acute myocardial infarction treated with primary angioplasty: implications for early discharge. Circulation 2004; 109:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/46/16106/abstract/65\">",
"      Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 72 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16106=[""].join("\n");
var outline_f15_46_16106=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152207030\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIME FROM SYMPTOM ONSET ON OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H269830214\">",
"      Late PCI to open an occluded artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TIME FROM HOSPITAL ARRIVAL (DOOR-TO-BALLOON TIME) ON OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18640015\">",
"      Outcomes in patient subgroups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H269831116\">",
"      - Early versus late presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H269831123\">",
"      - Patient risk category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H233520420\">",
"      TIME FROM CONTACT WITH THE HEALTHCARE SYSTEM (SYSTEM DELAY)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233520601\">",
"      Direct transfer from the field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H233521064\">",
"      Transfer from a non-PCI center",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H233521475\">",
"      - False positive cath lab activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106809928\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152206999\">",
"      OTHER FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hospital performance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Performance improvement strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      IMPORTANCE OF LOCAL EXPERTISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hospital and operator volume",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PCI without on-site cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS AFTER PRIMARY PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443272219\">",
"      TIMI flow grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443272427\">",
"      Electrocardiographic markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H443272420\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/72\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/72|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/18/31021\" title=\"figure 1\">",
"      Mortality and time to reperfusion in MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 2A\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 2B\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/72|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/49/1819\" title=\"table 1\">",
"      TIMI flow grades",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/59/4027\" title=\"table 2\">",
"      Killip classification of acute MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/42/35500\" title=\"table 3\">",
"      Personnel and facility requirements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/31/44540\" title=\"table 4\">",
"      Requirements for patient and lesion selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/37/34396\" title=\"table 5\">",
"      Requirements for off-site surgical backup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/61/3036\" title=\"table 6\">",
"      CADILLAC risk score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5930?source=related_link\">",
"      Coronary artery patency and outcome after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9431?source=related_link\">",
"      Electrocardiographic diagnosis of myocardial infarction in the presence of bundle branch block or a paced rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/42/34473?source=related_link\">",
"      Percutaneous coronary intervention after fibrinolysis for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41769?source=related_link\">",
"      Prognosis after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35658?source=related_link\">",
"      Risk stratification for cardiac events after acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/31/37369?source=related_link\">",
"      Selecting a reperfusion strategy for acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_46_16107="Preventing lead exposure from paint";
var content_f15_46_16107=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Educational interventions to prevent exposure to lead in paint",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Clean up loose paint chips immediately",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wipe off loose paint using damp disposable cloths or rags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Block access to chipping paint with furniture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Put contact paper over chipping paint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hose off porch or place down a blanket or rug where children play",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seal or enclose areas with small amounts of chipping paint",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Do not use hazardous methods of removing paint:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sanding without a HEPA attachment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Open-flame burning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chemical removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use only certified abatement contractors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure family and belongings (eg, upholstered furniture) are protected during abatement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Environmental Protection Agency. (file://www.epa.gov/lead/educationexesum.htm)",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16107=[""].join("\n");
var outline_f15_46_16107=null;
var title_f15_46_16108="Neonatal outcome with IAI";
var content_f15_46_16108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neonatal outcome in intraamniotic infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Term",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Preterm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        IAI",
"       </td>",
"       <td class=\"subtitle2\">",
"        No IAI",
"       </td>",
"       <td class=\"subtitle2\">",
"        IAI",
"       </td>",
"       <td class=\"subtitle2\">",
"        No IAI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        92",
"       </td>",
"       <td>",
"        606",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gestational age (weeks)",
"       </td>",
"       <td>",
"        40.5",
"       </td>",
"       <td>",
"        40.2",
"       </td>",
"       <td>",
"        30.2",
"       </td>",
"       <td>",
"        31.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perinatal death (percent)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis (percent)",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumonia (percent)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grade III-IV intraventricular hemorrhage (percent)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Five-minute apgar &lt;7 (percent)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory distress (percent)",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        62",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IAI: intra-amniotic infection.",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from: Yoder, PR, Gibbs, RS, Blanco, JD, et al. Am J Obstet Gynecol 1983; 145:695 and Morales, WJ, Washington SR III, Lzar, AJ. J Perinatol 1987; 7:105.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16108=[""].join("\n");
var outline_f15_46_16108=null;
var title_f15_46_16109="Suppurative parotitis rx";
var content_f15_46_16109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60370&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual causative organisms and initial empiric antimicrobial regimens for suppurative parotitis in adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual causative organisms",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Initial antimicrobial regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Immunocompetent host",
"       </td>",
"       <td class=\"subtitle2\">",
"        Immunocompromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"10\">",
"        Staphylococcus aureus, viridans and other streptococci, Bacteroides spp, Peptostreptococcus spp, and other oral anaerobes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        <p>",
"         Nafcillin 1.5 g IV Q 4 h",
"         <sup>",
"          &loz;&sect;",
"         </sup>",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Linezolid 600 mg orally or IV Q 12 h",
"        </p>",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         Vancomycin 15-20 mg/kg IV Q 12 h or linezolid 600 mg orally or IV Q 12 h",
"         <strong>",
"          PLUS",
"         </strong>",
"         one of the following regimens:",
"        </p>",
"        <ul>",
"         <li>",
"          Cefepime 2 g IV Q 12 h",
"          <strong>",
"           PLUS",
"          </strong>",
"          metronidazole 500 mg IV Q 6-8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Imipenem 500 mg IV Q 6 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Meropenem 1 g IV Q 8 h",
"          <strong>",
"           or",
"          </strong>",
"         </li>",
"         <li>",
"          Piperacillin-tazobactam 4.5 g IV Q 6 h",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <p>",
"         Either metronidazole 500 mg IV Q 6-8 h",
"        </p>",
"        <p>",
"         <strong>",
"          or",
"         </strong>",
"        </p>",
"        <p>",
"         Clindamycin 600 mg IV Q 6-8 h",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Oral step-down regimens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Immunocompetent host",
"       </td>",
"       <td class=\"subtitle2\">",
"        Compromised host",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Clindamycin 450 mg orally Q 8 h",
"        <strong>",
"         plus",
"        </strong>",
"        ciprofloxacin 500 or 750 mg orally Q 12 h",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        Clindamycin 450 mg orally Q 8 h",
"        <strong>",
"         plus",
"        </strong>",
"        ciprofloxacin 750 mg orally Q 12 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Amoxicillin-clavulanate 875 mg orally Q 12 h +/- linezolid 600 mg orally Q 12 h",
"        <sup>",
"         &sect;������",
"        </sup>",
"       </td>",
"       <td class=\"centered\" rowspan=\"3\">",
"        Linezolid 600 mg orally Q 12 h",
"        <strong>",
"         plus",
"        </strong>",
"        moxifloxacin������ 400 mg orally Q 24 h",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Linezolid 600 mg orally Q 12 h",
"        <strong>",
"         plus",
"        </strong>",
"        moxifloxacin 400 mg orally Q 24 h",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The doses recommended in this table are intended for patients with normal renal and hepatic function.",
"     <br>",
"      &Delta; Immunocompromised hosts are at increased risk for facultative gram-negative bacilli, including extended-spectrum-&beta;-lactamase (ESBL)-producing Enterobacteriaceae and Pseudomonas aeruginosa.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       Vancomycin 15-20 mg/kg IV Q 12 h or linezolid 600 mg orally or IV Q 12 h should be substituted for nafcillin in hosts with risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection.",
"       <br>",
"        &sect; Risk factors for MRSA infection include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA.",
"        <br>",
"         &yen; The higher dose of ciprofloxacin should be used when Pseudomonas aeruginosa is suspected.",
"         <br>",
"          &Dagger; Linezolid should be included if MRSA is suspected.",
"          <br>",
"           &dagger; Moxifloxacin lacks adequate activity against P. aeruginosa, so it should not be used when this organism is suspected or proven to be the etiologic agent.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16109=[""].join("\n");
var outline_f15_46_16109=null;
var title_f15_46_16110="Speech sound development";
var content_f15_46_16110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Average age estimates and upper age limits of customary consonant production",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 584px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The solid bar corresponding to each sound starts at the median age of customary articulation; it stops at an age level at which 90 percent of all children are customarily producing sound. (From Templin, 1957; Wellman et al, 1931.)",
"    <div class=\"footnotes\">",
"     &Theta;: th as in \"those\"; &delta;: th as in \"thin\".",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: When are speech sounds learned? by E K Sander. Journal of Speech and Hearing Disorders, 37, 55. Copyright &copy; 1972 American Speech-Language-Hearing Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16110=[""].join("\n");
var outline_f15_46_16110=null;
var title_f15_46_16111="Choosing a primary procedure for pelvic organ prolapse";
var content_f15_46_16111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56020&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choosing a primary procedure for pelvic organ prolapse: Major decision points",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 592px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_46_16111=[""].join("\n");
var outline_f15_46_16111=null;
